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ABSTRACT 
Oxysterol binding protein-related protein 2 (ORP2) is a member of mammalian 
oxysterol binding protein (OSBP)-related protein/gene family, which is found in 
almost every eukaryotic organism. Their function is still unclear, but studies on 
yeast and mammalian cells have suggested that they are players in cellular lipid 
metabolism, vesicle trafficking and cellular signaling. ORP2 is a cytosolic protein 
that is ubiquitously expressed and most abundant in brain. In previous studies 
employing stable cell lines with constitutive ORP2 overexpression ORP2 was shown 
to affect cellular cholesterol metabolism.  
The aim of this study was to characterize the properties and function of ORP2 
further. Since the previous studies have shown that ORPs bind sterols and 
phosphoinositides, the binding of those lipids was also tested using purified ORP2 in 
in vitro binding assays. As expected, ORP2 was shown to bind several oxysterols 
and cholesterol, the highest affinity ligand being 22(R)hydroxycholesterol. In 
addition, affinity to anionic membrane phospholipids, phosphatidylinositol 
phosphates was observed, which may assist in the membrane targeting of ORP2. 
Intracellular localization of ORP2 was investigated to obtain clues to the function of 
ORP2. ORP2 was observed on the surface of cytoplasmic lipid droplets, which are 
storage organelles for neutral lipids. Lipid droplet targeting of ORP2 was inhibited 
when 22(R)hydroxycholesterol was added to the cells or when the N-terminal 
FFAT-motif of ORP2 was mutated, suggesting that oxysterols and the N-terminus of 
ORP2 regulate the localization and thereby also the function of ORP2.  
The role of ORP2 in cellular lipid metabolism was studied using HeLa cell lines that 
can be induced to overexpress ORP2. In that way the acute effects of protein 
overexpression can be detected. Overexpression of ORP2 was shown to enhance 
cholesterol efflux from the cells resulting in a decreased amount of cellular free 
cholesterol. ORP2 overexpressing cells responded to the loss of cholesterol by 
upregulating the cholesterol synthesis and uptake. Intriguingly, cholesterol 
esterification was increased in ORP2 overexpressing cells. These results may be 
  
explained by the ability of ORP2 to bind and thus transport cholesterol, which most 
likely leads to changes in cholesterol metabolism when ORP2 is overexpressed.  
ORP2 function was also investigated using an opposite approach, silencing of 
endogenous ORP2 expression with short interfering RNAs (siRNA) in A431 cells. 
Silencing of ORP2 led to a delayed break-down of triglycerides under lipolytic 
conditions and an increased amount of cholesteryl esters in the presence of excess 
triglycerides. Together these results suggest that ORP2 is a sterol-regulated protein 
that functions on the surface of cytoplasmic lipid droplets to regulate the metabolism 
of triglycerides and cholesteryl esters. Although the exact mechanism of ORP2 
function still remains unclear, this study serves as a good basis to investigate the 
molecular mechanisms and possible cell type specific functions of ORP2. 
 
 
Keywords: oxysterol, oxysterol binding protein, ORP2, cholesterol, triglyceride, 
lipid droplet 
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TIIVISTELMÄ 
ORP2 on oksisteroleja sitovan proteiinin (OSBP) sukuisen proteiini- ja geeniperheen 
jäsen. OSBP:n sukuisia proteiineja (ORP) löytyy lähes kaikista aitotumallisista 
organismeista. Näiden proteiinen tehtävää ei ole vielä selvitetty, mutta tutkimukset 
hiiva-ja nisäkässoluilla ovat osoittaneet, että ORP:it osallistuvat solun rasva-
aineenvaihdunnan, vesikkelikuljetuksen ja signaalinvälityksen säätelyyn. ORP2 on 
solulimassa ilmentyvä proteiini. Sitä ekspressoidaan kaikissa kudoksissa, eniten 
kuitenkin aivoissa. Aiemmissa tutkimuksissa, joissa on käytetty ORP2:a ylituottavia 
soluja, on havaittu ORP2:n vaikuttavan solunsisäiseen kolesteroliaineenvaihduntaan 
Tämän tutkimuksen tarkoituksena oli selvittää tarkemmin ORP2:n ominaisuuksia ja 
tehtävää solun rasva-aineenvaihdunnassa. Koska useiden ORP:ien oli aiemmin 
havaittu sitovan steroleja ja fosfoinositideja, määritimme ORP2:n kyvyn sitoa näitä 
rasvoja käyttäen in vitro sitomiskokeita puhdistetulla ORP2-proteiinilla. ORP2 sitoi 
eri oksisteroleja ja kolesterolia, sitoutumisen ollessa vahvinta 
22(R)hydroksikolesteroliin. ORP2:n havaittiin myös sitovan solun kalvoissa 
sijaitsevia anionisia fosfolipidejä, fosfatidyyli-inositolifosfaatteja. Tämän sitomisen 
arvellaan edistävän ORP2:n liittymistä solun kalvoihin. 
Tutkimuksessa selvitettiin ORP2:n sijaintia solussa. ORP2 havaittiin solunsisäisten, 
neutraaleja rasvoja sisältävien rasvapisaroiden pinnalla. Kun soluille lisättiin 
22(R)hydroksikolesterolia, ORP2 siirtyi pois rasvapisaroiden pinnalta. Myös 
ORP2:n aminoterminuksessa sijaitsevan FFAT-motiivin mutatoiminen aiheutti 
ORP2:n poistumisen rasvapisaroiden pinnalta, viitaten siihen, että oksisterolit ja 
ORP2:n aminoterminaalinen osa säätelevät ORP2:n sijaintia solussa ja siten myös 
sen tehtävää. 
ORP2:n tehtävää solun rasva-aineenvaihdunnassa tutkittiin HeLa-solulinjoilla, jotka 
voidaan indusoida tuottamaan ORP2-proteiinia. Tällä metodilla voidaan havaita 
proteiinin ylituotannon välittömät vaikutukset solun aineenvaihduntaan. ORP2:n 
ylituotanto lisäsi kolesterolin virtausta ulos solusta. Tämä johti vapaan kolesterolin 
määrän vähenemiseen soluissa. ORP2:a tuottavat solut pyrkivät lisäämään 
kolesterolin määrää kiihdyttämällä kolesterolin valmistusta ja sisäänottoa. Yllättäen 
myös kolesterolin esteröinti oli kiihtynyt ORP2:a tuottavissa soluissa. Näiden 
  
tulosten arveltiin aiheutuvan ORP2:n kyvystä sitoa ja mahdollisesti myös kuljettaa 
kolesterolia, mikä voi johtaa muutoksiin kolesterolin aineenvaihdunnassa, kun 
ORP2:a tuotetaan soluissa suuria määriä. 
ORP2:n toimintaa tutkittiin myös päinvastaisella lähestymistavalla, hiljentämällä 
ORP2:n ilmentyminen A431-soluissa käyttäen pieniä häiritseviä RNA-molekyylejä 
(siRNA). ORP2:n hiljentäminen johti triglyseridien hajotuksen viivästymiseen 
hajotusta edistävissä olosuhteissa ja kolesteroliesterien määrän lisääntymiseen, kun 
triglyseridejä oli soluissa runsaasti. Tässä väitöskirjatyössä saadut tulokset viittaavat 
siihen, että ORP2 on sterolien säätelemä proteiini, joka sijaitsee solun 
rasvapisaroiden pinnalla, missä ORP2 osallistuu triglyseridien ja kolesteroliesterien 
aineenvaihduntaan. Vaikka ORP2:n tarkka toimintamekanismi jäi selvittämättä, 
tämän tutkimuksen pohjalta on hyvä jatkaa ORP2:n molekyylitason toiminnan ja 
mahdollisten solutyyppispesifisten tehtävien tutkimista.    
 
 
Avainsanat: Oksisteroli, oksisteroleja sitova proteiini, ORP2, kolesteroli, 
triglyseridi, rasvapisara 
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ABBREVIATIONS 
ACAT Acyl-coenzyme A:cholesterol acyl transferase 
ABC ATP-binding cassette transporter 
ARF ADP-ribosylation factor 
ATGL Adipose triacylglycerol lipase 
BSA Bovine serum albumin 
CEH Cholesteryl ester hydrolase 
CERT Ceramide transport (protein) 
CHO  Chinese hamster ovary (cells) 
CYP cytochrome P450 
DGAT acyl-CoA:diacylglycerol acyltransferase 
DRM detergent-resistant membrane 
ER Endoplasmic reticulum 
FBS Fetal bovine serum 
FFAT Two phenylalanines in an acidic tract  
HDL High density lipoprotein 
HMG-CoA  3-hydroxy-3-methylglutaryl coenzyme A  
HSL Hormone sensitive lipase 
Insig Insulin-induced gene 
LDL Low-density lipoprotein 
LPDS Lipoprotein deficient serum 
LXR Liver X receptor   
MS Mass spectrometry 
OHC Hydroxycholesterol 
ORD OSBP-related domain 
ORP OSBP-related protein  
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OSBP Oxysterol binding protein 
OSH/Osh OSBP homologue 
PH Pleckstrin homology (domain) 
PIP Phosphatidylinositol phosphate  
PKA Protein kinase A 
PUFA Polyunsaturated fatty acid 
SREBP Sterol regulatory element binding protein 
Scap SREBP cleavage activating protein 
SMase sphingomyelinase 
VAP Vesicle-associated membrane protein-associated protein  
7KC 7-ketocholesterol 
24,25EC 24(S),25-epoxycholesterol 
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1 INTRODUCTION 
Cholesterol is an essential molecule for mammalian cells. It is a precursor of steroid 
hormones, bile acids and other signaling molecules, but most importantly it is an 
essential constituent of cell membranes. An appropriate amount of cholesterol is 
needed for the plasma membrane to function as a barrier between intracellular and 
extracellular compartments and to relay the extracellular signals inside the cell.  
The proper amount of cholesterol in the body – in the cells and in the blood – is 
important for human health. Excess cholesterol in the blood can accumulate in the 
vessel walls and together with other factors contribute to the formation of 
atherosclerosis, a major cause of death in Western societies. Although 
atherosclerosis is commonly seen as a disease of the extracellular milieu, many ways 
to prevent or cure it are based on intracellular mechanisms.  
Oxysterols are oxidized derivatives of cholesterol, which can form passively by 
autoxidation or be synthesized by specific enzymes. Because of their reactivity they 
are difficult to study. In addition, their levels in the body are very low resulting in 
questioning their relevance in vivo. There is a wide variety of different oxysterols, 
but their distinct roles have remained mainly unclear. On one hand, they are 
regarded toxic and harmful, but on the other hand they can inhibit cholesterol 
biosynthesis and stimulate cholesterol export from the body thus performing 
beneficial actions, with regard to the prevention of atherosclerosis.  
One proof of the importance of oxysterols is the presence of oxysterol binding 
protein-related protein family (ORP) in eukaryotic organisms. The founding member 
of the family, oxysterol binding protein (OSBP) was discovered in the 1980s and its 
precise function is still unknown. It has been shown to be involved in various 
cellular processes such as signal transduction and sphingomyelin metabolism. OSBP 
has also been demonstrated to affect the lipid levels in the circulation of genetically 
modified mice suggesting that the ORPs may play roles in the development of 
atherosclerosis. Therefore it is important to study their functions more thoroughly.   
This study focused on ORP2. It is a ubiquitously expressed protein suggesting that it 
has an important function in many tissues. ORP2 was shown to bind cholesterol and 
several oxysterols. It was found to localize on the surface of intracellular lipid 
droplets, and the localization was inhibited by its ligand binding. ORP2 
overexpression influenced cholesterol metabolism in cultured cell lines and ORP2 
silencing affected also triglyceride metabolism. Therefore we propose that ORP2 
could function to create a regulatory connection between cholesterol and triglyceride 
metabolism.  
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2 REVIEW OF THE LITERATURE 
2.1 Intracellular cholesterol metabolism 
Much is known about the cholesterol circulation in the body – how it is transported 
between organs in the lipoprotein particles. In contrast, intracellular cholesterol 
metabolism and trafficking have many fundamental questions that have remained 
unanswered. The amount of cholesterol in membranes varies a lot between 
organelles, implying that intracellular cholesterol is not passively distributed around 
the cell but rather transported inside the cell via carefully controlled routes. 
2.1.1 Uptake of cholesterol 
Uptake of cholesterol is maybe the best characterized event in cellular cholesterol 
trafficking. Cholesterol destined to be taken up by peripheral cells is transported in 
the circulation in low-density lipoprotein (LDL) particles, mostly in an esterified 
form. Peripheral cells take up the whole LDL particle via the LDL receptors (Brown 
and Goldstein, 1986). First apo B-100 apolipoprotein in LDL binds to LDL receptor 
and then the LDL-LDL receptor-complex is internalized by clathrin-mediated 
endocytosis. During the maturation, endosomes become more acidic and 
subsequently the LDL receptor is released from the LDL particle and transferred 
back to the plasma membrane. LDL is transported to the later endosomal 
compartments, where apo B-100 is degraded and cholesteryl esters are hydrolyzed to 
free cholesterol and fatty acids by acid lipase. After that the faith of cholesterol is 
less well known (Ikonen, 2008). Cholesterol is delivered from late endosomal 
systems to other cellular membranes by processes that involve Niemann-Pick 
disease type C (NPC) proteins, the defect of which causes accumulation of 
cholesterol in the lysosomes (Sturley et al., 2004). Possible destinations of the LDL-
derived cholesterol are the plasma membrane, endoplasmic reticulum (ER), 
recycling endosomes and mitochondria.  
Uptake of cholesterol is mainly regulated by the amount of LDL receptors in the 
plasma membrane. The expression of LDL receptor gene is known to be upregulated 
by sterol regulatory element binding proteins (SREBP), which are active when the 
level of cellular sterols is low (Goldstein et al., 2006). 
LDL in the circulation is also found in oxidized form. In the arterial intima 
macrophages take up oxidized LDL via scavenger receptors by a process that is not 
regulated by cellular cholesterol levels (Greaves and Gordon, 2008). This can lead to 
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a situation, in which macrophages that already contain enough cholesterol still take 
up oxidized LDL resulting in the formation of macrophage foam cells. Therefore 
this process contributes to the development of atherosclerosis. 
2.1.2 Synthesis of cholesterol 
Lipoprotein internalization is not the only way of getting cholesterol into the cell. 
All nucleated mammalian cells are capable of synthesizing cholesterol from a 
ubiquitous precursor, acetyl-CoA, which is an activated degradation product of 
carbohydrates, amino acids and lipids. Biosynthesis of cholesterol (Figure 1) is a 
long series of reactions by over 40 cytosolic and membrane-bound enzymes that are 
mainly thought to reside in the ER membranes (Liscum, 2008).  
The first reaction of the synthesis pathway is the condensation of acetyl-CoA and 
acetoacetyl-CoA catalyzed by 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase. 
HMG-CoA is then reduced to mevalonate by HMG-CoA reductase, which is a rate-
limiting enzyme of the pathway. The six-carbon mevalonate is converted to a five 
carbon isopentenyl pyrophosphate, which is also the precursor of isoprenoids. Six 
molecules of isopentenyl pyrophosphate are condensed to the thirty-carbon 
isoprenoid, squalene, which is further made cyclic to form the first sterol of the 
pathway, lanosterol. Three carbons are then removed in two alternative series of 
reactions to yield the 27-carbon cholesterol.   
Cholesterol synthesis is regulated mainly at the level of HMG-CoA reductase by 
feedback mechanisms, which affect the expression, phosphorylation and degradation 
of the enzyme (Espenshade and Hughes, 2007). When the cellular sterol level is low, 
SREBP transcription factors stimulate the transcription of the HMG-CoA reductase 
gene. When the sterol level is high, cholesterol and oxysterols induce the 
inactivation of the SREBP pathway. In addition, sterol intermediates such as 
oxysterols, lanosterol and 24,25-dihydrolanosterol induce the degradation of HMG-
CoA reductase by ubiquitin-proteasome dependent pathway (Ravid et al., 2000; 
Song and DeBose-Boyd, 2004; Song et al., 2005), which also requires Insig protein 
(Sever et al., 2003). The activity of HMG-CoA reductase is also regulated by the 
energy status of the cell. When the supply of nutrients and subsequent ATP levels in 
the cell are low, AMP-activated kinase phosphorylates and thus inactivates HMG-
CoA reductase (Carling et al., 1989). HMG-CoA reductase is a target of cholesterol 
lowering drugs such as statins that occupy the HMG binding site thus being 
reversible, competitive inhibitors of the enzyme (Istvan and Deisenhofer, 2001). 
Statins decrease the amount of cellular cholesterol and subsequently upregulate the 
LDL receptor thus decreasing the LDL-cholesterol in the plasma.  
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Figure 1. Important intermediates of cholesterol biosynthesis. 
2.1.3 Cholesterol efflux 
An atherosclerotic lesion contains macrophages that are filled with cholesteryl esters 
originated from plasma lipoproteins. These cells are called foam cells and they have 
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a great impact on lesion progression. Therefore the stimulation of macrophage 
cholesterol efflux is an interesting goal for pharmaceutical research.  
Cholesterol efflux is a process in which cholesterol is transferred from the cell 
surface either to a high-density lipoprotein (HDL) particle or to a lipid-poor 
apolipoprotein such as apoA-I or apoE.  The goal of this process is to transport 
excess cholesterol from the peripheral cells to the liver, which is the only organ 
capable of excreting cholesterol out of the body in the bile and faeces. The whole 
process is called reverse cholesterol transport.  
Cholesterol efflux can be either passive or active. In passive diffusion cholesterol is 
released from the membrane to phospholipid-containing acceptors without need for 
energy-consuming protein mediators. In active cholesterol efflux proteins facilitate 
the export of cholesterol to extracellular acceptors (Jessup et al., 2006). Two of the 
known mediators of cholesterol efflux belong to a family of ATP-binding cassette 
(ABC) transporters, which are membrane proteins that use the energy of ATP to 
move substances up the concentration gradient. The first ABC transporter found to 
be involved in cholesterol efflux was ABCA1, the gene of which is disturbed in a 
Tangier’s disease (Bodzioch et al., 1999; Brooks-Wilson et al., 1999; Rust et al., 
1999). This disease leads to an accumulation of intracellular cholesterol and loss of 
HDL in the plasma due to a defective cholesterol efflux process. The role of ABCA1 
is to promote cholesterol and phospholipid efflux to lipid-poor apoA-I particles, 
which leads to the formation of nascent, lipidated HDL-particles. The precise 
mechanism of ABCA1 function is not yet known, but it has been postulated that 
ABCA1 has dual roles in cholesterol efflux. First, it binds to apoA-I and directly 
promotes the lipidation of apoA-I. Secondly, it affects the lipid distribution in the 
plasma membrane so that cholesterol is more easily extracted from the membrane by 
apoA-I (Landry et al., 2006). According to a third model ABCA1 is endocytosed 
with apoA-I via a clathrin-mediated pathway and recycled back to the plasma 
membrane (Azuma et al., 2009). This mechanism was found to be important only 
when cells accumulated lipoprotein-derived cholesterol.  
Because ABCA1 deficient cells are still capable of removing cholesterol, other 
mediators were searched and found (Klucken et al., 2000). ABCG1 is a protein that 
resides in an intracellular location. When the cells are loaded with cholesterol, it 
translocates to the plasma membrane and mediates cholesterol efflux to HDL 
particles (Wang et al., 2006). A sequential model has been proposed, in which 
ABCA1 first induces the formation of HDL-particle by helping cholesterol and 
phospholipids lipidate apoA-I, after which ABCG1 can mediate the efflux of 
cholesterol to HDL (Gelissen et al., 2006). Scavenger Receptor B1 (SR-B1) has also 
been suggested to participate in cholesterol efflux from peripheral cells to HDL (Ji 
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et al., 1997). However, the main function of SR-B1 seems to be in the liver, where it 
mediates the uptake of cholesteryl esters from HDL. 
How is cholesterol efflux regulated? The expression of ABCA1 and ABCG1 in 
macrophages is strongly upregulated by high levels of cholesterol. Both genes 
contain an element responsive to liver X receptors (LXRs, see below). ABCA1 is 
also regulated at the posttranslational level. The stability, intracellular trafficking 
and activity of the ABCA1 protein can be controlled (Oram and Heinecke, 2005). 
2.1.4 Intracellular storage of cholesteryl esters and triglycerides 
Cell membranes have a limited capacity for free cholesterol. Therefore excess 
cholesterol has to be stored in an esterified form in the cytoplasmic lipid droplets. 
Esterified cholesterol can then be released when needed e.g. for steroid hormone 
synthesis, membrane renewal or signaling purposes. Triglycerides are also stored in 
lipid droplets. In adipocytes lipid droplets store energy for the whole body, but also 
other cell types store fatty acids as triglycerides to be used e.g. for phospholipid 
synthesis and signaling purposes.  
Lipid droplets are formed of a lipophilic core consisting mostly of triglycerides and 
cholesteryl esters (Walther and Farese, 2008). Phospholipid monolayer surrounds 
the core. Lipid droplets are thought to originate from the ER membranes but the 
mechanism of lipid droplet formation is still hypothetical. Lipid droplets are not 
only passive storage sacs of lipids but dynamic organelles that undergo fusions and 
fissions, interact with other organelles and move along microtubules. A variety of 
proteins are found on the surface of lipid droplets regulating these events. 
C h o l e s t e r o l  e s t e r i f i c a t i o n   
Cholesterol is esterified with long-chain fatty acyl-coenzyme A by Acyl-coenzyme 
A:cholesterol acyl transferases [ACAT, (Chang et al., 1993; Chang et al., 1997; 
Chang et al., 2009)]. Two genes encode two ACATs, which are integral membrane 
proteins residing in the ER (Anderson et al., 1998; Cases et al., 1998a; Oelkers et al., 
1998). ACAT1 is expressed in most tissues suggesting a role as a general regulator 
of free cholesterol homeostasis, whereas ACAT2 is expressed in enterocytes and 
hepatocytes possibly forming cholesteryl esters for secretion in lipoprotein particles. 
Also the transcription of ACAT genes is differently regulated. Cholesterol addition 
seems to increase the expression of ACAT2 by a still unknown mechanism, whereas 
the expression of ACAT1 was not affected by cholesterol in cultured hepatic cells 
(Pramfalk et al., 2007). The enzymatic activity of ACAT is regulated by sterols in an 
allosteric fashion. ACAT seems to have two sterol binding sites – one for the 
activator and one for the substrate – that differ in their ability to accommodate 
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different sterols (Zhang et al., 2003). The other ACAT substrates, fatty acids 
upregulate ACAT activity as well (Seo et al., 2001). The preferred substrate and 
activator for ACAT1 was found to be oleic acid, whereas ACAT2 had broader 
substrate specificity. In addition to cholesterol, oxysterols can increase ACAT 
activity (Brown et al., 1975) and also be esterified by ACAT (Zhang et al., 2003).  
Because ACAT is responsible for cholesterol esterification in macrophages hence 
contributing to the formation of foam cells, it has been studied as a target for 
pharmaceutical inhibition (Meuwese et al., 2006). Although the animal studies were 
promising, people treated with ACAT inhibitors did not benefit from the treatment. 
C h o l e s t e r y l  e s t e r  h y d r o l y s i s  
Hydrolysis of cholesteryl esters is less studied than esterification although it is 
necessary for the removal of cholesterol from the lipid droplet and out of the cell. 
Cholesteryl esters derived from LDL-particles are hydrolysed by lysosomal acid 
cholesteryl ester lipase. Cholesteryl esters stored in the lipid droplet are hydrolysed 
by neutral cholesteryl ester hydrolase (CEH), the human gene of which was cloned 
in 2000 from monocyte/macrophages (Ghosh, 2000). Liver CEH was later 
characterized and proposed to participate also in bile acid synthesis (Zhao et al., 
2005b). CEH is localized to the surface of lipid drolets in macrophages (Zhao et al., 
2005a) and it has been found to be identical with triacylglycerol hydrolase (TGH), 
(Dolinsky et al., 2004). In addition, hormone sensitive lipase (HSL) can hydrolyze 
cholesteryl esters suggesting that the same enzymes may be responsible for 
hydrolyzing cholesteryl esters and triglycerides. A recent study showed that mice 
lacking HSL had increased level of plasma cholesterol and hepatic cholesteryl esters 
supporting the fact that HSL is important in hydrolysis of both triglycerides and 
cholesterol esters (Fernandez et al., 2008). There are also other triglyceride 
hydrolases that have not yet been characterized and that might also catalyze the 
hydrolysis of cholesteryl esters.  
T r i g l y c e r i d e  s y n t h e s i s   
The last step in triglyceride (triacylglycerol) synthesis is acylation of diacylglycerol 
with fatty acyl-CoA by quite recently identified acyl-CoA:diacylglycerol 
acyltransferase (DGAT) enzymes (Cases et al., 1998b; Cases et al., 2001; Yen et al., 
2008). DGAT1 and DGAT2 are expressed from different genes and even belong to 
different protein families. DGAT1 is a member of a family of membrane-bound O-
acyltransferases, in which the ACATs belong as well. DGAT1 is ubiquitously 
expressed and DGAT2 is also expressed in most tissues. Both genes have the highest 
expression levels in tissues that synthesize high amounts of triglycerides, such as 
liver, adipose tissue and mammary gland. DGAT2 has been shown to be more 
potent than DGAT1 in triglyceride synthesis as shown by in vitro activity assays and 
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by knock-down mouse model studies (Yen et al., 2008), suggesting that it is 
responsible for the most of the triglyceride synthesis for long-term storage. In 
contrast to DGAT2, DGAT1 can acylate other molecules than diacylglycerol (Yen et 
al., 2005). It can also synthesize triglyceride from monoacylglycerol by two 
subsequent esterifications, suggesting a role in the reesterification of hydrolyzed 
triglycerides.  
Like the ACATs, the DGAT enzymes are integral membrane proteins residing in ER 
membranes. Whether they release the synthesized triglycerides in ER lumen or to 
the cytosolic compartment is not completely understood. It is suggested that the 
triglycerides destined to be secreted in lipoproteins are synthesized by DGAT1 and 
are thus released to the ER lumen. Triglycerides that are to be stored in lipid droplets 
are suggested to be synthesized by DGAT2 and to be released to the cytoplasm as a 
constituent of lipid droplet. Interestingly, it was recently reported that DGAT2 can 
also be found on the surface of lipid droplets, where it could synthesize triglyceride 
directly to the lipid droplet for storage (Kuerschner et al., 2008).  
H y d r o l y s i s  o f  t r i g l y c e r i d e s  
Two proteins contributing to the breakdown of triglycerides have been characterized 
so far, adipose triacylglycerol lipase (ATGL) and HSL (Zimmermann et al., 2004; 
Fredrikson et al., 1981; Watt and Steinberg, 2008). The removal of the first fatty 
acid from triglyceride is catalyzed by ATGL. The resulting diacylglycerol is a 
preferred substrate of HSL. This enzyme hydrolyzes diacylglycerol to 
monoacylglycerol, which is finally hydrolyzed by monoacylglycerol lipase to yield 
glycerol and a free fatty acid.   
Lipolysis is mainly regulated at the post-translational level (Zimmermann et al., 
2008). The classical activation of lipolysis is initiated by catecholamines. They bind 
to -adrenergic receptors at the cell surface and stimulate G-protein coupled 
receptors, which activate adenylase cyclase to produce more cyclic AMP (cAMP). 
cAMP binds to protein kinase A (PKA), which leads to phosphorylation and 
subsequent activation of lipolytic proteins. HSL is phosphorylated by PKA. 
However, its phosphorylation has not been considered as important for hormone 
stimulated lipolysis as the phosphorylation of the coactivator protein, perilipin. A 
recent model suggests that in basal, unstimulated conditions perilipin is on the 
surface of lipid droplets. When it is phosphorylated by PKA in the stimulated 
condition, it interacts with HSL and promotes the translocation of HSL from the 
cytosol to lipid droplets and the catalysis of the lipolysis. Unphosphorylated 
perilipin also interacts with the ATGL activator CGI-58 (comparative gene 
identification-58; Lass et al., 2006), which was earlier identified as a gene defective 
in neutral lipid storage disease Chanarin-Dorfman Syndrome (Lefevre et al., 2001). 
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When perilipin is phosphorylated, CGI-58 is released and is able to activate ATGL. 
The mechanism of lipolysis is still quite unclear. Although the role of perilipin in 
adipocytes is much studied, it is not ubiquitously expressed. It is not expressed for 
example in muscle and liver, where ATGL and CGI-58 play important roles. 
However, there are many members in the perilipin family of lipid droplet proteins, 
which may contribute to the control of lipolysis in other cell types (Brasaemle, 
2007). 
2.1.5 Transcriptional regulation of cellular cholesterol homeostasis 
S t e r o l  r e g u l a t o r y  e l e m e n t  b i n d i n g  p r o t e i n  ( S R E B P )  
The main function of SREBP transcription factors is to maintain the cellular 
cholesterol and lipid homoeostasis (Brown and Goldstein, 1999). Two SREBP genes 
encode three isoforms. SREBP-2 regulates mainly the genes involved in cholesterol 
uptake and synthesis whereas SREBP-1c activates the genes of fatty acid synthesis 
(Horton et al., 2003). SREBP-1a regulates all SREBP responsive genes.  
All the SREBP isoforms function in the same way. SREBP precursors are 
synthesized in the ER membranes as transmembrane proteins and subsequently 
bound to SREBP cleavage activating protein (Scap). Scap is an ER membrane 
protein that has a sterol sensing domain, by which it can sense the level of 
cholesterol. When the cholesterol level in the ER is low, Scap binds to COPII coat 
proteins of ER exiting vesicles and the SREBP-Scap complex is transported to the 
Golgi complex. In Golgi SREBP is cleaved by two proteases to yield a soluble, 
active fragment that can enter the nucleus and activate genes that have a sterol 
responsive element (SRE) in their promoter. When the cholesterol level in the ER 
rises, sterol binding of Scap induces a conformational change that permits the 
binding to Insig (insulin-induced gene; Yang et al., 2002). This leads to the retention 
of SREBP-Scap in the ER, because Scap can no longer bind to COPII proteins (Sun 
et al., 2005).  
Recent studies have revealed the importance of Insig proteins in the regulation of 
cholesterol homeostasis. To date two Insig proteins (Insig-1 and -2) have been 
identified (Yabe et al., 2002; Yang et al., 2002). They function in the same way, but 
their transcription is differently regulated. The expression of Insig-1 requires 
SREBP activation, whereas Insig-2 is constitutively expressed at a low level. 
Through SREBP pathway sterol depletion increases the Insig-1 mRNA level. On the 
other hand, sterol depletion decreases the Insig-1 protein level, because when Insig-
1 is not bound to Scap (in sterol depleted cells), it becomes ubiquitinated and 
degraded in proteasomes (Gong et al., 2006). Insig-1 also mediates the effect of 
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oxysterols on SREBP regulation, because unlike Scap it is able to bind oxysterols 
(Radhakrishnan et al., 2007). Oxysterol-bound Insig binds to Scap and thus blocks 
the transport of the SREBP-Scap complex to Golgi apparatus.    
L i v e r  X  r e c e p t o r s  ( L X R s )  
While the SREBP system aims at increasing the cellular cholesterol content by 
upregulating cholesterol uptake and synthesis, LXRs activate the genes involved in 
the stimulation of cholesterol export out of the cells and out of the body (Zelcer and 
Tontonoz, 2006). Two LXRs have been identified: LXR is highly expressed in the 
liver and at low levels in the adrenal glands, intestine, adipose tissue, macrophages, 
lung and kidney, whereas LXR is ubiquitously expressed (Repa and Mangelsdorf, 
2000). LXRs form heterodimers with retinoid X receptor (RXR) (Willy et al., 1995). 
They reside in the nucleus bound to the LXR-responsive elements of target genes 
and in the inactive state form a complex with corepressors of transcription. 
LXR/RXR heterodimers can be activated by the ligand of either partner, which leads 
to the exchange of corepressor to coactivator and subsequent transcription of target 
genes. Natural ligands of LXRs were unknown for a long time, but finally they were 
recognized to be oxysterols (Janowski et al., 1996; Lehmann et al., 1997). 
The first LXR target gene was identified from Lxra-/-mice (Peet et al., 1998). It was 
CYP7A1, encoding a rate-limiting enzyme of the classical pathway of bile acid 
synthesis. The cholesterol efflux-mediating proteins ABCA1 (Repa et al., 2000a) 
and ABCG1 (Venkateswaran et al., 2000) were later identified as LXR target genes 
as well as two other ABC transporters ABCG5 and ABCG8 (Repa et al., 2002). 
ABCG5 and -8 form a heterodimer that appears to limit the absorption of sterols in 
the intestine and mediate the biliary sterol excretion from the hepatocytes (Repa et 
al., 2002). Considering these target genes, LXR agonists seemed perfect drug 
candidates for treating atherosclerosis by stimulating cholesterol export out of the 
body. However, Schultz et al. found that treating mice and hamster with LXR 
agonists increased the triglyceride level of plasma and liver (Schultz et al., 2000). 
This was found to result from LXR-dependent upregulation of SREBP-1c, the gene 
of which contains an LXR response element (Repa et al., 2000b) and which itself 
upregulates the transcription of genes involved in fatty acid synthesis. This 
mechanism is suggested to decrease the amount of free cholesterol by providing 
oleic acid for cholesterol esterification. Unfortunately it is also an obstacle for using 
LXR agonists as lipid lowering drugs. 
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2.2 Oxysterols 
Oxysterols are oxygenated cholesterol derivatives that have additional oxygen in the 
nucleus of the sterol ring structure or in the iso-octyl tail of cholesterol (often 
referred as side-chain oxysterols) (Figure 2). Because of the additional oxygen they 
are more hydrophilic than cholesterol, which makes them more accessible to 
cytosolic oxysterol receptors and thus better signaling molecules of cellular sterol 
status than cholesterol itself. Because of their greater hydrophilicity and ability to 
pass lipophilic membranes faster than cholesterol, they are also regarded as transport 
forms of cholesterol that mediate the excretion of sterol out of the body. However, 
the physiological concentration of oxysterols in healthy tissue is very low, which 
makes them more difficult to study and the studies on oxysterol effects often 
unreliable. Oxysterols are regarded as cytotoxic and increased concentrations of 
oxysterols are often connected with pathological conditions such as atherosclerosis 
Brown and Jessup, 1999). 
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Figure 2. A. The structure of cholesterol with numbered carbon atoms. B. Structures of 
oxysterols mentioned in the text. 
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2.2.1 The formation and properties of oxysterols 
Oxysterols are formed in tissues by autoxidation or by the action of specific 
monooxygenases. (van Reyk et al., 2006). They can also be obtained from diet. 
Autoxidative oxysterols form when radicals attack the cholesterol molecule, most 
commonly on the 7-carbon, which results in the formation of 7-hydroxycholesterols, 
mainly the 7-hydroxycholesterol (7-OHC), and 7-ketocholesterol (7KC). These 
oxysterols have been found in very small amounts in the body usually in esterified 
and thus less harmful form. However, they have been detected in higher levels in 
sites of cholesterol accumulation, such as macrophage foam cells and atherosclerotic 
plaques (Brown and Jessup, 1999).  
Different enzymes can hydroxylate cholesterol either in the side-chain or in the 
sterol ring (Russell, 2000). Most of the responsible enzymes are cytochrome P450 
(CYP) enzymes that reside in various subcellular locations. 7-hydroxycholesterol 
(7-OHC) is produced by cholesterol 7-hydroxylase (CYP7A1) in a reaction that is 
also the first committed step in the classical bile acid synthesis pathway. CYP7A1 
can also hydroxylate several oxysterols (Norlin et al., 2000). 20(S)- and 
22(R)hydroxycholesterols are formed by cytochrome P450scc as intermediates in 
the biosynthetic pathway of pregnenolone, which is a precursor of streroid hormones 
(Hume et al., 1984). Cholesterol 24-hydroxylase (CYP46) produces 
24(S)hydroxycholesterol (24OHC), which is relatively abundant in brain, more 
exactly in the neurons (Lund et al., 1999). 27-hydroxycholesterol (27OHC, 
previously known as 26-hydroxycholesterol) is produced by sterol 27-hydroxylase 
(CYP27A1), a mitochondrial enzyme that is expressed in many tissues with the 
highest expression level in macrophages (Wikvall, 1984; Javitt, 2002a). CYP27A1 
has broad substrate specificity; it also hydroxylates 7-OHC in the 27-carbon in the 
synthetic pathway of bile acids. Cholesterol 25-hydroxylase differs from the other 
cholesterol hydroxylases by belonging to a family of non-heme iron containing 
proteins (Lund et al., 1998). It catalyzes the formation of 25-hydroxycholesterol, 
which is a minor oxysterol in the body and often regarded as an autoxidation 
product, formed in the sample processing. 24(S),25-epoxycholesterol (24,25EC) is 
not a cholesterol derivative, but is formed in a shunt pathway of cholesterol 
biosynthesis by the action of oxidosqualene cyclase (Nelson et al., 1981). The rate of 
24,25EC synthesis has been found to correlate with that of cholesterol (Wong et al., 
2007), thus making it an attractive candidate for a feed-back regulator of cholesterol 
biosynthesis. 
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2.2.2 Biological functions of oxysterols 
O x y s t e r o l  e f f e c t s  o n  c h o l e s t e r o l  b i o s y n t h e s i s  
Oxysterols first started to gain interest when they were found to inhibit cholesterol 
biosynthesis in cells (Brown and Goldstein, 1974; Kandutsch and Chen, 1974). 
Based on these and other studies Kandutsch et al. proposed that oxysterols function 
as feedback regulators of cholesterol biosynthesis (Kandutsch et al., 1978). In 1984 
Taylor et al. discovered a cytosolic protein that binds oxysterols with affinities that 
correlate with their ability to inhibit cholesterol synthesis (Taylor et al., 1984). 
Oxysterol binding protein (OSBP) was therefore thought to mediate the oxysterol 
effects on cholesterol synthesis. However, Nishimura et al. showed much later with 
gene silencing studies that the cholesterol synthesis inhibition by oxysterols is 
independent of OSBP (Nishimura et al., 2005). The role of oxysterol binding to 
OSBP and its later discovered relatives has not yet been solved.  
Radhakrishnan et al. found that oxysterols, namely 25OHC, 22(R)OHC, 24(S)OHC, 
27OHC and 24,25EC deactivate the SREBP pathway by binding to Insig, which 
then retains Scap-SREBP in the ER thus inhibiting the cholesterol biosynthesis 
(Radhakrishnan et al., 2007). Oxysterol binding to Insig also induces the interaction 
between HMG-CoA reductase and Insig, which then triggers the ubiquitination and 
subsequent degradation of HMG-CoA reductase (Sever et al., 2003; Song and 
DeBose-Boyd, 2004). This is in accordance with the finding that 27OHC is 
necessary for Insig-mediated degradation of HMG-CoA reductase in rapid response 
to high cholesterol levels (Lange et al., 2008). Based on this study Lange et al. 
proposed that oxysterols are responsible for the rapid inactivation of HMG-CoA 
reductase, whereas cholesterol itself takes care of the down-regulation taking place 
in hours through the SREBP/Scap pathway. 
O x y s t e r o l s  a s  L X R  l i g a n d s  
In addition to Insigs, oxysterols have been shown to be ligands to Liver X receptors 
(LXR) in vitro and subsequently activate their function as transcription factors 
(Janowski et al., 1996; Lehmann et al., 1997). The best ligands were found to be 
side-chain oxysterols 24(S)OHC, 24,25EC and 22(R)OHC, that bound to LXRs in 
concentrations comparable to those found in cells (Janowski et al., 1999). 7- or 
7βOHC were not able to bind to or activate LXRs in the same study. It has been 
uncertain for a long time, if the LXR activation by oxysterols occurs also in vivo. 
Finally, Chen et al. showed that if the action of oxysterols is blocked by 
overexpressing a sulfotransferase enzyme that catalyzes the sulfonation of 
oxysterols in mice, they no longer respond properly to dietary cholesterol by 
upregulating the LXR target genes (Chen et al., 2007). This was also the case with 
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mice lacking the functional genes of 24(S)OHC, 25OHC and 27OHC biosynthetic 
enzymes, proving that oxysterols do activate LXRs also in vivo.  
O t h e r  r o l e s  o f  o x y s t e r o l s  
Previous results suggest that oxysterols affect cholesterol metabolism by binding to 
the Insig and LXR proteins. However, Gale et al. recently suggested that also the 
modulation of membrane properties by side-chain oxysterols can affect SREBP 
processing and HMG-CoA reductase degradation (Gale et al., 2008). This was based 
on studies in which enantiomeric 25OHC defective in interacting with protein 
receptors was able two exert similar effects as 25OHC. The membrane behavior of 
oxysterols differs from that of cholesterol (Massey, 2006). Oxysterols position 
themselves in the membranes in a very different way from cholesterol, because it is 
energetically favorable to position both hydrophilic groups near the water interface. 
This may lead to a tilted orientation of oxysterols in the membrane (Kauffman et al., 
2000). Therefore oxysterols differ from cholesterol and also from each others in 
their ability to promote the formation of liquid ordered domains depending on the 
position of the extra hydroxyl group (Massey and Pownall, 2006).  
Due to their increased hydrophilicity, oxysterols transfer between membranes much 
faster than cholesterol (Theunissen et al., 1986). Side-chain oxysterols such as 
24OHC and 27OHC were transferred from red blood cells to plasma much faster 
than cholesterol or oxysterols hydroxylated in the sterol nucleus (Meaney et al., 
2002). Indeed, the most abundant oxysterols in human circulation are 27OHC and 
24(S)OHC, as determined by isotope dilution-mass spectrometry (Dzeletovic et al., 
1995). 24OHC is most abundant in brain (Björkhem, 2007), where the cholesterol 
24-hydroxylase is expressed at relatively high level. Knocking down cholesterol 24-
hydroxylase gene in mice resulted in reduced cholesterol biosynthesis in brain, while 
the over-all cholesterol levels were similar to wild-type mice (Lund et al., 2003). 
This could mean that since the cholesterol is not exported from the brain in the form 
of 24OHC, the cholesterol synthesis is slowed down. It is thus tempting to speculate 
that 24OHC is a transport form of excess brain cholesterol, since it can pass 
lipophilic membranes and probably the blood-brain barrier, which is impermeable to 
plasma lipoproteins.  
27OHC in turn, besides being a ligand of LXRs and Insigs, is a precursor of bile 
acids in hepatocytes (Javitt, 2002a; Javitt, 2002b). It is also relatively abundant in 
human atherosclerotic plaques and macrophage-derived foam cells (Brown and 
Jessup, 1999). The function of 27OHC has been been studied using cells derived 
from humans suffering from cerebrotendinous xanthomatosis (CTX). This disease is 
characterized by the lack of functional sterol 27-hydroxylase (Cali et al., 1991). It 
leads to neurological defects and premature atherosclerosis most probably caused by 
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abnormal deposition of cholesterol and cholestanol in many tissues, although the 
cholesterol levels in the circulation are normal (Leitersdorf et al., 1994). 
Interestingly, mice with disrupted sterol 27-hydroxylase gene displayed less severe 
defects, although the formation of bile was diminished (Rosen et al., 1998). 27OHC 
has recently been found to bind to estrogen receptors in vascular wall and thus 
inhibit estrogen function (Umetani et al., 2007). 
The best acknowledged function for oxysterols is their role as precursors of bile 
acids (Javitt, 2002b). Bile acids are formed in the liver and secreted to the intestine 
via gallbladder. In intestine they facilitate the absorption and digestion of fats and 
fat-soluble molecules by acting as detergents. Bile acid synthesis is also the major 
pathway through which cholesterol is eliminated from the body. The classical 
pathway of bile acids synthesis takes place in the liver. There cholesterol is first 
hydroxylated at the 7-position by CYP7A1. 7-hydroxylated oxysterols can also 
form via an alternative pathway, in which oxysterols such as 24OHC, 25OHC and 
27OHC that are formed in different organs are 7-hydroxylated by CYP7B1 and 
CYP39A1. The latter reactions are common for both pathways and take place in the 
liver.   
It is commonly thought that the most reliable studies on oxysterol action are not the 
ones, in which exogenous oxysterols are added to cells or to animals, but those 
employing models in which genes encoding an oxysterol forming or degrading 
enzymes are knocked out. These studies have usually failed to show dramatic effects 
of the lack of one oxysterol. This suggests that individual oxysterols can take over 
the action of others and, on the other hand, cholesterol hydroxylases can add the 
hydroxyl group also to other positions (Lund et al., 1993). These studies also show 
that oxysterols affect cholesterol homeostasis, but in a very delicate manner, which 
is not yet completely understood.  
2.3 OSBP 
2.3.1 Discovery of OSBP 
In 1977 Kandutsch et al. found cytosolic protein fractions capable of binding 25-
hydroxycholesterol (Kandutsch et al., 1977). This protein fraction was characterized 
and purified further by the same group. Oxysterol binding protein (OSBP) was later 
purified from hamster liver and a monoclonal antibody produced by the group of 
Brown and Goldstein (Dawson et al., 1989b). Rabbit OSBP cDNA was cloned in 
1989 (Dawson et al., 1989a), human cDNA in 1990, and the OSBP gene was 
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localized to human chromosome 11 (Levanon et al., 1990). By the year 1992 many 
tools were thus available to study the function of OSBP in the cell.    
2.3.2 Structural properties of OSBP  
Oxysterol binding region of OSBP was first found to reside between amino acids 
296 and 809 (Ridgway et al., 1992). Later the sterol-binding region was narrowed to 
amino acids 408-459, which contain a CRAC (cholesterol recognition/interaction 
amino acid consensus) motif, implicated in sterol binding by other proteins (Wang et 
al., 2008). According to three-dimensional structure of yeast ORP, Osh4p, these 
amino acids are not in the region of the -barrel suggested to form the sterol-binding 
pocket (see figure 4 of Osh4p). Instead these amino acids are thought to reside in the 
lid region of OSBP. To explain this discrepancy Wang et al. proposed that OSBP 
binds sterols using the lid region and inserts the sterol to the sterol binding pocket.  
The N-terminal part of OSBP was recognized to contain a pleckstrin homology (PH) 
domain (Musacchio et al., 1993). These domains are found in many proteins with 
variable functions (Lemmon, 2008). A common feature for many PH domains is that 
they bind phosphatidylinositol phosphates (PIP) in cellular membranes. PIPs can be 
phosphorylated at positions 3, 4 and 5 depending on the organelle and the PI-kinases 
or phosphatases localizing to that specific membrane. Therefore the PIP binding 
specificity of a PH domain can determine the membrane where it is localizing. In the 
study of Rameh et al. OSBP was shown to bind PI(4,5)P2 and PI(3,4,5)P3 (Rameh et 
al., 1997), but Levine and Munro later proposed that the binding of PI(4)P is more 
important regarding the subcellular targeting of the OSBP PH domain (Levine and 
Munro, 2002).  
The first 87 amino acids in the N-terminus of OSBP were identified as a glycine-
alanine rich domain (Dawson et al., 1989a). This domain was shown to reduce the 
cholesterol binding of OSBP without affecting the 25OHC binding (Wang et al., 
2008). OSBP was also shown to contain a putative leucine zipper motif at amino 
acids 209-244, the role of which has remained unsolved (Dawson et al., 1989a). 
OSBP has also been shown to dimerize (Ridgway et al., 1992), and the responsible 
protein region was found to reside between amino acids 261-288 (Wyles et al., 
2002).  
2.3.3 Intracellular localization of OSBP 
In standard growth conditions OSBP is cytosolic or localizes to small vesicular 
structures adjacent to the nucleus. When 25OHC was added to cells OSBP was 
found to translocate to the Golgi apparatus (Ridgway et al., 1992). The N-terminal 
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part, which was later found to contain a PH domain, localized constitutively to Golgi 
apparatus suggesting that the C-terminal oxysterol binding domain, which was 
identified in the same study, negatively regulates the Golgi localization in the 
absence of ligand. The studies of Neale Ridgway’s group showed that the 
cholesterol depletion of cells by different manipulations induces a constitutive 
localization of OSBP to the Golgi apparatus independent of 25OHC addition 
(Mohammadi et al., 2001; Storey et al., 1998). Wang et al. later proposed that 
cholesterol binding of OSBP induces the masking of the PH domain resulting in 
cytosolic localization. In contrast, when oxysterol is bound, PH domain is 
predisposed resulting in the translocation of OSBP to Golgi apparatus (Wang, P.Y. 
et al., 2005). 
Levine and Munro showed that the PH domain of OSBP is sufficient for the Golgi 
localization and that the targeting is dependent on PI(4,5)P2 or PI(4)P binding 
(Levine and Munro, 1998). Other Golgi specific factors were still needed, since 
PI(4,5)P2 is found also in other membranes. Later Levine and Munro showed using 
yeast mutant strains that the Golgi localization of the OSBP PH domain is dependent 
on PI-4-kinase activity and not on PI(4)P 5-kinase activity, proving that the OSBP 
PH domain binds PI(4)P in the Golgi membranes (Levine and Munro, 2002). 
However, an OSBP mutant defective in PIP binding still had some affinity towards 
Golgi membranes and in yeast this affinity required the activity of Arf1p (ADP-
ribosylation factor), which is needed for the recruitment of various proteins to Golgi 
apparatus. Indeed, Godi et al. found that the PH domain of OSBP interacts directly 
with ARF and even stimulates its Golgi association (Godi et al., 2004), supporting a 
specific role for OSBP in the Golgi membrane trafficking. 
OSBP was later found to also have affinity towards ER-membranes. When the Golgi 
association was disturbed by mutating the PH domain of OSBP, OSBP was found in 
the ER compartment with Vesicle-associated membrane protein-associated protein 
A (VAP-A; Lev et al., 2008), which was recognized as an interaction partner of 
OSBP in a yeast two-hybrid screen (Wyles et al., 2002). Interestingly, silencing the 
expression of VAP inhibited also the Golgi targeting of OSBP, even in the presence 
of 25OHC, which could be explained by a decreased amount of PI(4)P in the Golgi 
membranes of VAP silenced cells (Peretti et al., 2008). Interaction with VAP-A was 
mapped to amino acids 351-442 of OSBP (Wyles et al., 2002), which was later 
shown to contain a FFAT-motif (two phenylalanines in an acidic tract) that mediates 
the VAP interaction of many lipid binding proteins (Loewen et al., 2003). 
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2.3.4 The role of OSBP in sphingomyelin metabolism 
The study of Storey et al. (1998) hypothesized for the first time that OSBP could be 
involved in cholesterol or oxysterol dependent regulation of sphingomyelin 
synthesis, because the stimulatory effect of 25OHC on sphingomyelin synthesis 
correlated with changes in OSBP localization and phosphorylation status. The link 
between these two phenomena was still missing. In the next study Ridgway et al. 
observed that the depletion of plasma membrane sphingomyelin by exogenously 
added bacterial sphingomyelinase (SMase) induced the dephosphorylation of OSBP 
(Ridgway et al., 1998). SMase was also shown to induce the Golgi localization of 
OSBP. The role of OSBP in sphingomyelin metabolism was investigated in the next 
study, which employed OSBP overexpressing CHO cells (Lagace et al., 1999). In 
this study OSBP overexpressing cells were able to enhance the 25OHC stimulated 
sphingomyelin synthesis, although the enzymatic activities of sphingomyelin 
synthesising enzymes in vitro were not altered. This implied that OSBP could affect 
the substrate availability of these enzymes, which would make sense since these 
enzymes reside in Golgi, where OSBP is translocated upon 25OHC treatment. This 
hypothesis got support from the next study (Wyles et al., 2002). Overexpression of 
OSBP mutant W174A, which localized constitutively to ER membranes together 
with VAP-A, was blocking the transport of fluorescent ceramides from ER to Golgi 
resulting in reduced synthesis of sphingomyelin.  
RNA interference studies and the discovery of CERT (ceramide transport) protein 
(Hanada et al., 2003) helped to produce a mechanistic model of OSBP function in 
25OHC mediated stimulation of sphingomyelin synthesis (Perry and Ridgway, 
2006). CERT is a ceramide binding protein required for ceramide transport from ER 
to Golgi apparatus, where sphingomyelin synthesis takes place (reviewed in 
(Hanada et al., 2007). OSBP is required for the Golgi localization of CERT only in 
the presence of 25OHC whereas VAP-A is needed for the ER association of CERT. 
Rescue experiments of OSBP depleted cells by OSBP mutants showed that the PH 
domain, FFAT-motif and oxysterol binding were all needed for 25OHC mediated 
stimulation of sphingomyelin synthesis (Perry and Ridgway, 2006). However, OSBP 
was not required for CERT action in basal sphingomyelin synthesis and neither have 
the two proteins been shown to interact.  
In summary, OSBP functions in the connection between sphingomyelin and 
cholesterol metabolism. These two have to be connected, because cholesterol and 
sphingomyelin have a special property of forming liquid ordered domains together 
in the plasma membrane, which is important for the function of many membrane 
receptors (Simons and Ikonen, 1997). Although 25OHC is not a good oxysterol for 
cellular studies because of its low abundance in vivo, it can be thought to reflect the 
 34 
amount of cellular cholesterol. Therefore, in the presence of 25OHC the synthesis of 
sphingomyelin could be stimulated in order to maintain the appropriate ratio of 
sphingomyelin and cholesterol. OSBP binds to 25OHC and translocates to Golgi 
apparatus to stimulate the transport of ceramide by CERT, which then leads to 
increased synthesis of sphingomyelin. 
2.3.5 The effect of OSBP on cholesterol metabolism 
The effect of OSBP on cellular cholesterol homoeostasis has been studied by 
overexpressing OSBP in CHO cells (Lagace et al., 1997). Cholesterol esterification 
was reduced in OSBP overexpressing cells compared to mock-transfected cells and 
also the incorporation of [3H]oleic acid to triglycerides was slightly inhibited. 
Furthermore, cholesterol biosynthesis and LDL receptor gene expression were 
upregulated. These results were obtained when the cells were grown in delipidated 
serum containing medium showing that OSBP overexpressing cells try to increase 
the cellular free cholesterol levels even more than the control cells. This could be 
due to enhanced sphingomyelin synthesis reported later (Storey et al., 1998) or due 
to the sequesteration of cellular sterols by overexpressed OSBP. OSBP 
overexpression can also lead to altered cholesterol transport, since OSBP was 
recently demonstrated to be able to transport cholesterol between PI(4)P containing 
vesicles (Ngo and Ridgway, 2009).  
OSBP was also shown to affect cholesterol efflux by regulating the stability of the 
ABCA1 protein involved in the cholesterol efflux to apoA-I (Bowden and Ridgway, 
2008). Silencing of OSBP stabilized ABCA1 protein without affecting its mRNA 
levels. Concordantly, overexpression of OSBP destabilized ABCA1. This regulation 
seemed to be independent of the effect of OSBP on sphingomyelin synthesis and to 
require the functional sterol binding domain. 
2.3.6 The role of OSBP in intracellular signaling 
Already in the early studies OSBP antibody recognized two bands in the purified 
sample, 96 kDa and 101 kDa (Dawson et al., 1989a), which were later found to 
represent the phosphorylated and non-phosphorylated forms of OSBP (Ridgway et 
al., 1998). OSBP was also found to be dephosphorylated in cells depleted of 
cholesterol (Storey et al., 1998) and in cells where the plasma membrane 
sphingomyelin was depleted by exogenously added bacterial SMase (Ridgway et al., 
1998). Dephosphorylation of OSBP seemed to result from the action of okadaic acid 
sensitive phosphatase PP2A, which is activated by ceramides and which later turned 
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out to be an interaction partner of OSBP (Wang, P.Y. et al., 2005). The 
phosphorylation sites of OSBP were mapped by Mohammadi et al. (2001). 
A new function for OSBP was discovered in 2005, when Wang et al. found that 
OSBP is an essential part of a protein complex that contains two phosphatases 
(Wang, P.Y. et al., 2005). Based on their findings they proposed a model in which 
the cholesterol binding of OSBP induces its interaction with PP2A phosphatase and 
phosphatase HePTP, which belongs to a family of PTPPBS tyrosine phosphatases. 
Removal of cellular cholesterol or addition of 25OHC induces the disassembly of 
this complex, leading to an increase in the amount of phosphorylated extracellular 
signal-regulated kinase (ERK). Later they localized the HePTP binding to a coiled-
coil domain in the C-terminus of OSBP (Wang et al., 2008).  
Another potential function for OSBP was found in studies with liver cells (Yan et 
al., 2007b). Adenoviral overexpression of OSBP in mouse liver was shown to 
increase the amount of triglycerides in very low density lipoprotein fraction and also 
in liver. This was accompanied by stimulated expression of SREBP-1c and its target 
genes involved in triglyceride and fatty acid synthesis. In accordance, OSBP 
silencing in cultured liver cells inhibited the triglyceride synthesis and the insulin 
stimulated induction of SREBP-1c responsive genes. These results can be linked to 
the function of OSBP as a regulator of ERK signaling, because SREBP-1c has been 
shown to be a target of ERK phosphorylation (Kotzka et al., 1998).  
In hypothetical summary, OSBP relays the signal of cholesterol depletion to the 
phosphatase complex by disassembling it when not bound to cholesterol. The 
disassembly leads to an increased amount of phosphorylated ERK1/2 kinases, which 
can then phosphorylate and thus activate nuclear SREBP (Kotzka et al., 2000) to 
induce the expression of genes involved in the uptake and synthesis of cholesterol. 
2.4 OSBP-related proteins  
2.4.1 Mammalian ORPs 
Human OSBP-related proteins (ORPs) were discovered later than their yeast 
relatives. Six of them, ORP1-6 were found in the search for cDNA sequences 
homologous to the sterol-binding domain of OSBP using the EST (expressed 
sequence tag) sequence database (Laitinen et al., 1999). In the next studies of two 
independent groups five additional human ORPs were found, cDNAs of all eleven 
ORPs established and their exon-intron structures and the chromosomal locations 
determined (Jaworski et al., 2001; Lehto et al., 2001). Functional domains were also 
predicted (Figure 3). All the human ORPs were found to contain an OSBP-related 
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domain (ORD) in their C-terminal half. In the middle of this domain they all have a 
fingerprint sequence EQVSHHPP, which can also be found in the ORPs of other 
species. Except for ORP2 all the full-length proteins have a PH domain in their N-
terminus and ORP5 and ORP8 have a C-terminal transmembrane sequence, 
structures that predict ORPs to be associated with membranes. In later studies most 
of the ORP genes were found to encode several protein isoforms due to alternative 
splicing. Human ORPs were also divided up into six subgroups according to their 
genomic organization and amino acid homology (Jaworski et al., 2001; Lehto et al., 
2001). 
ORP8
ORP5
ORP9S
ORP9L
ORP11
ORP10
ORP6
ORP7
ORP3 (2)
ORP3 (1)
ORP2
ORP1L
ORP1S
ORP4L
ORP4S
OSBP
I
II
III
IV
V
VI
 
Figure 3. A schematic figure of mammalian ORPs. Different subgroups are specified by 
Roman numerals. ORD is shown in red, OSBP-fingerprint in yellow, PH 
domain in blue, FFAT-motif in pink, ankyrin repeats in green, dimerisation 
domains in orange, leucine repeats in purple and transmembrane domain in 
light blue.   
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O R P 1  
The ORP1 gene has been shown to encode two isoforms, ORP1Short (ORP1S) and 
ORP1Long (ORP1L) (Johansson et al., 2003). The size of ORP1S is 50 kDa and it 
consists only of the OSBP-related domain. ORP1L is 108 kDa in size and it 
additionally has a PH domain and three ankyrin repeats, which are usually mediating 
protein-protein interaction in proteins with variable functions (Mosavi et al., 2004). 
These two isoforms also differ in their tissue expression pattern. ORP1S displays the 
highest expression in skeletal muscle and heart while ORP1L is most abundant in 
brain and lung (Johansson et al., 2003). ORP1L expression was also shown to be 
over 100-fold upregulated during the differentiation of monocytes to macrophages, 
whereas ORP1S expression displayed only 3-5-fold upregulation (Johansson et al., 
2003), suggesting that ORP1L has an important role in this differentiation process or 
in macrophages.  
The subcellular localizations of ORP1S and ORP1L are also different. ORP1S is 
evenly distributed throughout the cytoplasm and ORP1L localizes to Rab7-positive 
late endosomes (Johansson et al., 2003). The late endosomal targeting is dependent 
on the ankyrin repeats. The PH domain of ORP1L was shown to bind several 
phosphoinositides with low specificity and affinity, but was not necessary for the 
late endosomal targeting of ORP1L (Johansson et al., 2005), although it was able to 
strengthen the membrane interaction of ORP1L.  
The ankyrin repeat region of ORP1L was shown to mediate the interaction of 
ORP1L with the active form of the late endosomal protein Rab7 (Johansson et al., 
2005). The overexpression of ORP1L in HeLa cells stabilized the active form of 
Rab7, thus increasing its membrane association. ORP1L overexpression also 
induced the clustering of late endosomes to the perinuclear area. Rab7 mediated the 
interaction of ORP1L and RILP, another Rab7 effector protein (Johansson et al., 
2007). Together these three proteins form a complex that controls the dynein-driven, 
minus-end directed microtubular movement of late endosomes. Interestingly, 
ORP1L also interacts with an adenoviral protein RID, which is suggested to mimic 
the active form of Rab7 in host cells (Shah et al., 2007). 
The role of ORP1L in lipid metabolism was studied using ORP1L transgenic mouse 
macrophages (Yan et al., 2007a). Cholesterol efflux to HDL2 particles was inhibited 
in ORP1L expressing macrophages, while the efflux to apoA-I was not changed 
compared to wild-type cells. In parallel, the expression of ABCG1 and apoE was 
down-regulated in ORP1L macrophages. These results could at least partly explain 
the major finding of the study – the transplantation of ORP1L expressing 
macrophages to LDL receptor knock-out mice resulted in larger atherosclerotic 
lesions than the transplantation of macrophages from wild-type mice. 
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ORP1S function has been studied only in yeast cells, in which it was found to affect 
Golgi-derived vesicle transport (Fairn and McMaster, 2005a; Xu et al., 2001) 
Despite the lack of a PH domain ORP1S was shown to have affinity to acidic 
phospholipids, although the specificity has varied between experiments (Fairn and 
McMaster, 2005a; Xu et al., 2001). ORP1L has been shown to bind 22(R)OHC and 
25OHC (Yan et al., 2007a).   
O R P 2  
The ORP2 gene encodes a 55 kDa protein, which consists only of the OSBP-related 
domain. It does not have a PH domain, but was still reported to bind acidic 
phospholipids such as phosphatidic acid and PI(3)P (Xu et al., 2001). According to 
mRNA and protein expression data from human and mouse tissues, ORP2 is 
ubiquitously expressed (Laitinen et al., 2002). The expression level varies between 
tissues and the highest expression can be detected in brain. In mouse tissues 
polyclonal ORP2 antibody recognizes two bands with the molecular weights of 51 
kDa and 56 kDa, which could represent either two splice variants or post-
transcriptionally modified forms of ORP2.  
In CHO-K1 cells overexpressed ORP2 localized in part to the Golgi apparatus, but 
also cytosolic staining was observed (Laitinen et al., 2002). Constitutive 
overexpression of ORP2 in CHO-K1 cell lines had many effects on cellular 
cholesterol metabolism. Cholesterol efflux to 20% human serum, apoA-I and 
phosphatidylcholine vesicles was enhanced, and cholesterol esterification inhibited 
in ORP2 overexpressing cells compared to cells transfected with the control 
plasmid. Transient overexpression of ORP2 also caused a delay in the secretory 
pathway from the Golgi to the plasma membrane, which is in accordance with the 
result from Xu et al. showing the inhibitory effect of ORP2 on Golgi-derived vesicle 
transport in yeast (Xu et al., 2001). However, attention should be paid to the fact that 
Xu et al. used an ORP2 construct that is lacking amino acids 13-24.  
The effect of constitutive ORP2 overexpression on the cellular lipidome was studied 
in the CHO cell lines (Käkelä et al., 2005). In ORP2 overexpressing cells cultured in 
the standard medium the molar percentage of polyunsaturated fatty acids (PUFA) 
containing (diacyl) phosphatidylethanolamine, phosphatidylserine and 
phosphatidylinositol was increased. Furthermore, when the cells were cultured in 
medium containing lipoprotein deficient serum (LPDS), the relative amount of these 
lipids was decreased compared to control cells that displayed no change between the 
different culturing conditions. The amount of triglycerides and cholesteryl esters 
was decreased in ORP2 expressing cells. They also had less PUFAs in neutral lipids 
than the control cells, when cultured in normal medium. This suggests that ORP2 
either inhibits the synthesis of neutral lipids or enhances their degradation. When 
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cultured in LPDS containing medium, the amount of PUFAs in neutral lipids was 
not reduced as much in ORP2 overexpressing cells as in control cells, suggesting 
that PUFA-containing neutral lipids are more stable in ORP2 overexpressing cells. 
O R P 3  
ORP3 was first identified as a gene that had variable expression in hematopoietic 
cells (Gregorio-King et al., 2001). The ORP3 gene was later found to encode eight 
isoforms resulting from alternative splicing (Collier et al., 2003). These isoforms 
displayed distinct expression patterns. The full-length ORP3 was ubiquitously 
expressed, but substantial differences were found between tissues and cells at 
distinct stages of differentiation (Collier et al., 2003; Johansson et al., 2003; Lehto et 
al., 2004). ORP3 has also been found to be upregulated in many cancer tissues (see 
references in (Lehto et al., 2008)). Similar to most ORPs, ORP3 consists of a PH 
domain and OSBP-related domain and spaces in between. Four out of the eight 
ORP3 isoforms have a truncated OSBP-related domain. Full-length ORP3 shows a 
cytosolic distribution with apparent localization also at the plasma membrane and 
ER (Lehto et al., 2004). More careful examination revealed that the plasma 
membrane targeting of ORP3 is dependent on the PH domain, which is able to bind 
phosphoinositides PI(3,4)P2 and PI(3,4,5)P3 in a liposome pull-down assay (Lehto et 
al., 2005). In Hek293 cells endogenous ORP3 was also detected in the tips of cell 
membrane protrusions (Lehto et al., 2008). ER-targeting of ORP3 was dependent on 
the FFAT-motif, but also the flanking regions were required (Lehto et al., 2005). 
The FFAT-motif was also shown to mediate the VAP-A-binding of ORP3. 
Overexpression of both ORP3 and VAP-A resulted in the formation of rolled-up 
structures of ER-membranes, also known as organized smooth ER (OSER) (Snapp 
et al., 2003). This finding may be an artifact of protein overexpression or support the 
role of ORPs in membrane contact sites, due to targeting two membranes 
simultaneously (Olkkonen and Levine, 2004). The N-terminal half of ORP3 was 
demonstrated to respond to the conformational change induced by ligand binding in 
the C-terminal domain (Lehto et al., 2005). Since the ligands of the ORP3 ORD are 
not known, the oxysterol binding domain of ORP3 was replaced by the sterol 
binding domain of OSBP, which binds 25OHC. This chimeric construct was 
localizing to ER under normal culture conditions, but when 25OHC was added to 
the cells, ORP3:OSBP translocated to the plasma membrane, supporting the role of 
ligand binding in the regulation of ORP3 localization.  
More insight into the function of ORP3 was given by the finding that ORP3 interacts 
with R-Ras, a small GTPase that regulates cell adhesion, spreading and migration 
(Goldfinger et al., 2007; Lehto et al., 2008). Concordantly, ORP3 gene silencing and 
overexpression experiments suggested that ORP3 is a negative regulator of cell 
spreading and integrin activity, thus exhibiting effects opposite to those of active R-
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Ras. ORP3 was also shown to be phosphorylated and the phosphorylation was 
upregulated when the cells had no adhesive contacts (Lehto et al., 2008). 
O R P 6  a n d  O R P 7  
ORP6 and ORP7 belong to the same ORP subgroup as ORP3, but they have not 
been characterized in much detail. ORP6 mRNA displays the highest expression in 
brain and skeletal muscle and the expression in macrophages is significantly 
upregulated after loading with acetylated LDL (Lehto et al., 2001). ORP7 displays 
the highest expression in gastrointestinal tract and fetal lung (Lehto et al., 2004). 
The localization of overexpressed ORP6 was observed to be similar to ORP3 – 
association with the nuclear envelope, ER and plasma membrane could be detected 
(Lehto et al., 2004). ORP7 was detected partially associated with the ER.  
O R P 4  
ORP4 (also referred as OSBP2 and HLM, HeLa metastatic gene) is the closest 
homologue of OSBP. It was first identified as a gene that was upregulated in 
circulating tumor cells compared to healthy tissue and was therefore proposed to be 
a good marker of tumor metastasis (Fournier et al., 1999). ORP4 gene was reported 
to be highly expressed in retina but also in testis, fetal liver, brain, heart, muscle and 
kidney (Moreira et al., 2001; Wang et al., 2002). ORP4 gene was found to encode 
two isoforms, ORP4S (short isoform) and ORP4L (long isoform). ORP4L is similar 
to OSBP in its protein structure, but ORP4S has only an OSBP-related domain. Both 
isoforms bind 25OHC and cholesterol (Wyles et al., 2007). Both were also shown to 
associate with vimentin intermediate filaments. Overexpressed ORP4S caused the 
bundling and aggregation of these filaments, which was accompanied by inhibited 
esterification of LDL-derived cholesterol (Wang et al., 2002). The presence of a 
leucine repeat in ORP4L prevented the vimentin aggregation in ORP4L 
overexpressing cells (Wyles et al., 2007). ORP4L also has a short sequence that is 
highly homologous to the dimerisation domain of OSBP. This domain was found to 
mediate the interaction between ORP4L and OSBP (Wyles et al., 2007), which is the 
only interaction between different ORPs observed so far. 
O R P 5  a n d  O R P 8  
Basic characterization of ORP5 has not yet been done. However, it was recently 
demonstrated to play a role in the invasion of pancreatic cancer (Koga et al., 2008). 
Not only was high ORP5 expression connected with high invasiveness of cancer 
cells, but also overexpression and silencing studies of ORP5 suggested that the 
protein stimulates cancer cell invasion. Together with ORP8 it forms a subgroup IV. 
The common structural feature for them is a putative transmembrane domain in their 
C-terminus. The transmembrane domain mediates the association of ORP8 with ER 
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membranes and the OSBP-related domain mediates the binding of 25OHC (Yan et 
al., 2008). ORP8 expression is most abundant in liver, spleen, kidney, brain and 
adipose tissue. It is also highly expressed in human macrophages and was detected 
at high levels in human coronary artery atherosclerotic lesion macrophages. 
Interestingly, ORP8 gene silencing in human macrophage model was demonstrated 
to upregulate the expression of ABCA1 and enhance the cholesterol efflux to apoA-I 
suggesting that by inhibiting cholesterol efflux ORP8 could enhance the 
development of atherosclerotic lesions.  
O R P 9  
Like most other long ORPs, ORP9 is found as two splice variants, ORP9L and 
ORP9S, which consists only of the OSBP-related domain (Wyles and Ridgway, 
2004). Endogenous ORP9L localizes to Golgi membranes in CHO-K1 cells, but was 
also observed to associate with the ER, when overexpressed (Wyles and Ridgway, 
2004). Inducible overexpression of ORP9L in CHO-K1 cells was shown to disrupt 
the organization of ER and Golgi membranes (Wyles and Ridgway, 2004). 
Furthermore, the depletion of ORP9 led to the dispersion of Golgi markers and 
inhibition of ER-Golgi protein transport, suggesting that ORP9 is necessary for the 
integrity of Golgi in CHO cells (Ngo and Ridgway, 2009). Also the inducible 
overexpression of ORP9S led to fragmentation of Golgi. This was accompanied by 
inhibition of cell proliferation. ORP9 was also shown to be able to transport 
cholesterol from PI(4)P containing donor vesicles to acceptor vesicles (Ngo and 
Ridgway, 2009).  
ORP9 is also participating in PI3-kinase dependent signaling (Lessmann et al., 
2007). ORP9S was found to be highly expressed in human bone marrow-derived 
mast cells, in which it was demonstrated to be phosphorylated in a protein kinase Cβ 
(PKCβ) dependent way. ORP9 depletion was also shown to activate the 
phosphorylation of Akt in Hek293 cells and the two proteins were also found to 
form complexes with PKCβ. Through Akt ORP9 can therefore be linked to 
signaling cascades controlling the cell survival, cell cycle progression and glucose 
metabolism. 
C o m m o n  f e a t u r e s  o f  O R P s  
Although mammalian ORPs have been proposed to have their own distinct 
functions, they share many common features in addition to their homologous 
sequences. First of all, many of them interact directly or indirectly with small 
GTPases - OSBP with ARF, ORP1L with Rab7 and ORP3 with R-Ras. Many ORPs 
also show associations with the cytoskeleton. ORP1L is involved in the microtubule-
dependent transport; ORP3 seems to influence the actin cytoskeleton (Lehto et al., 
2008) and ORP4 associates with intermediate vimentin filaments. In addition, 
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ORP10 has been detected to localize on microtubules (J. Perttilä and V. M. 
Olkkonen, unpublished observation).  
A notable common feature of ORPs is that they have many determinants for 
intracellular targeting. The PH domain found in the long ORPs or phospholipid 
binding of the short ones targets them for example to the Golgi apparatus or to the 
plasma membrane. An FFAT motif or a transmembrane domain (in ORP8) targets 
the ER. Either the function of these determinants is regulated so that ORPs associate 
with one organelle at a time or ORPs are targeted to both organelles simultaneously 
at membrane contact sites. ER is found to form membrane contact sites with other 
organelles such as trans-Golgi network, plasma membrane, mitochondria, 
peroxisomes, lipid droplets, endosomes and lysosomes. ER is also a major organelle 
in which the lipid biosynthesis and the regulation of lipid metabolism take place. 
Through membrane contact sites lipids could be transported more easily without the 
need to transfer them over long distances. ORPs have been proposed to assist in the 
formation of membrane contact sites or in transporting lipids through them 
(Olkkonen and Levine, 2004)). The possibility that ORPs act as lipid transporter 
proteins has been studied more intensively in yeast.   
2.4.2 Yeast ORPs 
Yeast (Saccharomyces cerevisiae) does not have cholesterol in cellular membranes. 
Instead it can synthesize ergosterol, which closely resembles cholesterol in structure 
and in subcellular distribution (Zinser et al., 1993). Before discovering the 
mammalian homologues of OSBP, three OSBP-related genes were identified in 
budding yeast, namely SWH1 (OSH1 in current nomenclature), KES1 (OSH4) and 
HES1 (OSH5) (Jiang et al., 1994; Schmalix and Bandlow, 1994). The deletion of 
these genes was shown to affect the levels of membrane ergosterol (Jiang et al., 
1994). The whole yeast ORP family was identified and named OSH1-7 in the study 
of Beh et al. (2001). They also examined the effect of different combinations of 
OSH gene deletions on cell growth and ergosterol levels. Cells lacking one to six 
OSH genes were viable, but if all seven OSH genes were deleted, cells had a 
dramatic increase in their ergosterol levels and they did not survive. Deletion of each 
one of the OSH genes resulted in changes in gene expression that were distinct for 
each OSH (Beh et al., 2001). This suggests that the Osh proteins have independent 
roles, but also a common, essential function that most probably involves ergosterol 
metabolism.  
Beh et al. later proposed that the common role for Osh proteins involves the 
regulation of endocytosis (Beh and Rine, 2004). Deletion of all the OSH genes 
resulted in a disturbed ergosterol distribution and accumulation of intracellular lipid 
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droplets. Golgi-derived protein transport seemed to be unchanged, but endocytosis 
was severely inhibited. Whether the endocytosis defect resulted from changes in 
ergosterol distribution or was a direct consequence of OSH depletion remained to be 
clarified. It was also demonstrated that Osh-proteins are important for the polarized 
growth of yeast (Kozminski et al., 2006). They were found to be required for the 
proper polarized localization of small GTPases Cdc42p and Rho1p and also for a 
specific vesicular secretion pathway.  
The possible role of Osh proteins in nonvesicular sterol trafficking was studied using 
esterification of exogenously added sterol as an indicator of sterol trafficking from 
the plasma membrane to ER (Raychaudhuri et al., 2006). The yeast strains with Osh 
deletions displayed inhibited cholesteryl ester synthesis suggesting that Osh proteins 
transfer cholesterol from the plasma membrane to ER, which could be the common 
function of the Osh proteins. However, depletion of all OSH genes was found to 
result in a decreased amount of sterol in the plasma membrane as judged by filipin 
staining, suggesting the opposite (Beh and Rine, 2004). Osh proteins are so far the 
only putative nonvesicular sterol transport proteins in yeast. However, their deletion 
did not completely block the ergosterol transport from ER to the plasma membrane 
suggesting that there are other sterol transport pathways in yeast as well (Sullivan et 
al., 2006).  
O s h 4 / K e s 1 p  
Osh4p is the most studied ORP in yeast and it is also the first ORP that was 
crystallized in complex with different sterols (Im et al., 2005). Osh4p is a short ORP 
consisting only of the OSBP-related domain. It has a hydrophobic lipid binding 
pocket that is composed of -strands, which form a near-complete -barrel (Figure 
4). The N-terminus of Osh4p forms a lid that closes the barrel when a sterol is 
bound. Sterols are positioned in the barrel so that the 3-OH group is at the bottom 
and the side-chain is close to the lid. Hydroxyl groups in sterols do not make direct 
contacts with the amino acid side-chains of Osh4p, the contacts are rather mediated 
by water molecules. Osh4p could not be crystallized without a ligand. An apo 
structure of Osh4p without the lid was however obtained reflecting the unbound 
protein. The apo structure contained two regions that were buried in the ligand-
bound state but that were found on the surface of the apo structure making contacts 
with sulphate ions, which were thought to mimic the phosphate groups of PIPs. A 
model was thus constructed, in which the apo conformation attaches to the 
membrane with the help of PIPs and extracts cholesterol from the membrane or 
alternatively oxysterol from the solution. In the solution the protein-ligand complex 
is able to relay signals before it translocates to the acceptor membrane and unloads 
the lipid. This model is supported by the findings that Osh4p is able to transfer 
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sterols between liposomes in vitro (Raychaudhuri et al., 2006). The transfer was 
enhanced when PI(4,5)P2 was included in the liposomes. 
 
Figure 4. Structure of Osh4p in a complex with 25OHC (Protein Data Bank ID 1zhx). -
helical structures are colored in red and -strands in blue. 25OHC is colored in 
green and red, and the lid region (amino acids 1-29) in yellow. 
The first study on Osh4p suggested that the protein functions in the Golgi apparatus 
(Fang et al., 1996). Inactivation of the OSH4 gene resulted in survival of cells 
lacking the Sec14p function. Sec14p is a PI/PC-transfer protein essential for the 
transport of secretory proteins from Golgi apparatus. Deletion of any other Osh was 
not able to bypass the Sec14p deletion effect (Beh et al., 2001). Osh4p was thus 
proposed to be a negative regulator of Golgi function. Despite the lack of a 
conventional PH domain, Osh4p binds PI(4,5)P2. The binding was shown to be 
mediated by a region outside the ORD, which was proposed to be similar to PH 
domains (Li et al., 2002). However, based on the three-dimensional structural 
analysis of Osh4p, lysines 109 and 336 in the ORD were suggested to mediate the 
interaction with phosphate groups in phosphoinositides (Im et al., 2005), although 
the mutation in Lys109 did not inhibit the PIP binding in (Li et al., 2002). This 
mutation still abrogated the Golgi association of Osh4p (Li et al., 2002) supporting 
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the model of Im et al. Osh4p was also demonstrated to regulate Arf GTPase function 
(Li et al., 2002), a feature found also for OSBP.  
O t h e r  O s h - p r o t e i n s  
Localization of Osh1p supports nicely the function of ORPs in membrane contact 
sites. It localizes to nucleus-vacuole junction, which is a subcompartment of ER 
between the nuclear envelope and vacuole (Levine and Munro, 2001). This 
localization is mediated by the FFAT-motif and ankyrin repeats. The FFAT-motif 
also mediates the interaction of Osh1p, Osh2p and Osh3p with Scs2p, the yeast 
homologue of VAP-A (Levine and Munro, 2001; Loewen et al., 2003). Osh1p also 
has a conserved PH domain that mediates the targeting to the Golgi apparatus. In 
addition, Osh3p has a proposed function in the nucleus (Park et al., 2002). It 
interacts with a DEAD-box RNA helicase, Rok1p and is proposed to participate in 
the nuclear fusion and mitotic spindle formation (Park et al., 2002; Yano et al., 
2004). Osh6p and Osh7p were demonstrated to interact with Vps4p, a member of 
AAA (ATPases associated with a variety of cellular activities) protein family 
(Wang, P. et al., 2005). Deletion of Vps4p resulted in enhanced membrane 
association of Osh6p and Osh7p suggesting that it mediates the detachment of these 
proteins from the membrane.  
2.4.3 ORPs in other species 
Families of OSBP-related proteins can be found in practically all eukaryotic species. 
Like humans, mice also have twelve ORPs (Anniss et al., 2002). In addition, there 
are reports of ORPs in fruit fly (Drosophila melanogaster (Alphey et al., 1998)), 
roundworm (Caenorhabditis elegans (Sugawara et al., 2001)) and the parasitic 
protist Cryptosporidium parvum (Zeng and Zhu, 2006). Plants such as petunia and 
Arabidopsis thaliana were also demonstrated to have ORPs (Skirpan et al., 2006). 
The presence of ORPs throughout the eukaryotic kingdom suggests that they are 
important players in the cellular environment.   
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3 AIMS OF THE STUDY 
1.  To find the ligands of ORP2 
2. To determine the intracellular localization of ORP2 
3. To clarify the role of ORP2 in the intracellular lipid metabolism  
 
 47 
4 MATERIALS AND METHODS 
4.1 List of published methods 
Method Publication 
Recombinant DNA techniques II, III 
Cell culture and transfection I, III 
Expression and purification of recombinant proteins I, II, III 
SDS-PAGE and Western blotting I, II, III 
Lipid extraction and TLC I, III 
Liposome pull-down assay I 
Charcoal-dextran sterol-binding assay II, III 
Cholesterol binding assay III 
Immunofluorescence microscopy I, III 
Assay of cholesterol efflux I 
Isolation of detergent resistant membranes I 
Isolation of plasma membrane fraction using colloidal silica I 
Assay of cholesterol esterification I, III 
Enzymatic analysis of cellular cholesterol  I 
Assay of HMG-CoA reductase activity I 
Assays of uptake of endocytic markers I 
Assay of triglyceride hydrolysis III 
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4.2 Unpublished methods 
4.2.1 In vitro translation and VAP-A pull-down assay 
Wild-type ORP2 and the ORP2/FFAT-mutant were translated in vitro using 
[35S]methionine (>1000 Ci/mmol, GE Healthcare-Amersham) and the TnT-T7 
Coupled Reticulocyte Lysate System (Promega, Madison, WI) according to the 
manufacturer’s instructions. Twenty microliters out of the 50 μl in vitro reaction was 
incubated with 12 μg of GST-VAP-A(ΔTM) (A VAP-A construct that lacks the 
transmembrane domain) or plain GST in 100 μl PBS, 0.5% Triton X-100 for 45 min 
at room temperature. Glutathione sepharose 4B in PBS, 0.1% Triton X-100 was then 
added to the samples and incubated 30 min to bind the protein complexes. The 
matrix was washed three times with PBS, 0.1% Triton X-100 and boiled with SDS-
PAGE sample buffer. The samples were resolved on 12.5% SDS-PAGE gels, which 
were fixed and treated with Amplify (GE Healthcare-Amersham). The dried gels 
were exposed on X-ray films overnight at -70ºC. 
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5 RESULTS AND DISCUSSION 
5.1 Ligand binding of ORP2 
5.1.1 ORP2 binds phosphoinositides (I) 
Phosphatidylinositol phosphates (PIPs) are signaling lipids that form in cellular 
membranes by the action of organelle-specific kinases and phosphatases. Different 
signals affect the activity of these enzymes resulting in the acute formation of PIPs, 
which can mediate the targeting of PIP binding proteins to the membranes 
(Lemmon, 2008). The most common protein domain found to mediate the PIP 
binding is pleckstrin homology (PH) domain. This domain is found to regulate the 
membrane targeting of several ORPs.  
ORP2 does not have a PH domain. However, it has been shown to bind PI(3)P and 
phosphatidic acid (Xu et al., 2001). Xu et al. detected PIP binding using an assay, in 
which PIPs are immobilized on a nitrocellulose membrane and incubated with 
proteins, which are then recognized by antibodies. Nitrocellulose membrane is 
however an unnatural platform for lipids, and they may arrange in structures not 
found in cellular membranes.  Therefore we wanted to study the PIP binding using a 
more natural in vitro vesicle pull-down assay (Schiavo et al., 1996). In this assay 
PIPs are incorporated into phosphatidylcholine (PC) vesicles containing [14C]PC as 
a tracer. The vesicles are incubated with GST-fusion proteins bound to glutathione 
sepharose beads, which are then pulled down and the radioactivity associated with 
the pellet is measured using liquid scintillation counter. GST was used as a negative 
control, the results of which were subtracted from the GST-ORP2 results. GST-
tagged PH domain of phospholipase Cδ (PLCδ) was used as a positive control that 
binds PI(4,5)P2 with high affinity and specificity (Lemmon et al., 1995). [14C]PC 
vesicles without PIPs were used as control vesicles. Using this assay we observed 
that GST-ORP2 binds PI(3,4,5)P3 (I, fig. 9). Some affinity was also observed 
towards other PIPs probably resulting from non-specific electrostatic interaction 
between positively charged amino acids and the negative PIPs. The result of PI(3)P 
or phosphatidic acid binding by ORP2 (Xu et al., 2001) could not be repeated. The 
affinity of PI(3,4,5)P3 binding was not high, but may account for the membrane 
targeting of ORP2. However, PI(3,4,5)P3 is usually present transiently at low levels 
in the plasma membrane (Cantley, 2002), which means that PI(3,4,5)P3 binding 
proteins must have good affinity for it to mediate efficient downstream signaling.  
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Four other short ORPs lacking a PH domain, such as ORP1S, ORP9S, ORP10S and 
Osh4p, have been shown to bind PIPs as well (Fairn and McMaster, 2005b; Li et al., 
2002; Xu et al., 2001). This interaction could be mediated by positively charged 
amino acids on the protein surface. Indeed, based on the three-dimensional structure 
of Osh4p Im et al. suggested that two lysines in the positions 109 and 336 of Osh4p 
are buried in the sterol binding conformation, but are exposed to the protein surface 
when the ligand is not bound (Im et al., 2005). That way the sterol binding could 
affect the interaction of Osh4p with membranes via PIP binding.  
5.1.2 ORP2 binds oxysterols (II, III) 
The sterol ligand of ORP2 has been searched for in many ways, unsuccessfully (Xu 
et al., 2001). We were able to show in Cos7 cells that ORP2 binds [3H]-labeled, 
photo-activated 25OHC (II, fig. 4A). We wanted to confirm the binding in vitro by a 
charcoal-dextran sterol-binding assay using purified GST-fusion proteins and [3H]-
labeled 25OHC. Also the binding of 7KC, 22(R)OHC, 24(S)OHC and 27OHC was 
investigated. The best ORP2 ligand of the tested oxysterols was 22(R)OHC (III, fig. 
1a), the Kd being 1.4 x 10-8 M, which is close to the value of OSBP affinity for 
25OHC, 0.8-1.0 x 10-8 M (Dawson et al., 1989a; Dawson et al., 1989b). GST-ORP2 
showed also binding to 24(S)OHC (unpublished result, Kd was not determined), 
7KC (Kd 1.6 x 10-7) and 25OHC (Kd 3.9 x 10-6) (Figure 5; II, fig. 1D-E). The most 
interesting of these oxysterols is 24(S)OHC. We did not have sufficient amount of 
[3H]-labeled 24(S)OHC to perform the assay with multiple concentrations, but a 
single experiment suggested that the affinity of ORP2 towards 24(S)OHC is good. 
24(S)OHC is proposed to be important for the cholesterol transport from the brain 
(Björkhem, 2007). Because ORP2 is highly expressed in the brain, it would be forth 
studying if ORP2 specifically affects the function of 24(S)OHC.  
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Figure 5. Oxysterol binding of GST-ORP2 was tested using charcoal-dextran sterol-
binding assay of [3H]oxysterols. All the results are published in II and III 
except for the binding of 24(S)OHC (shown in red).   
To examine which amino acids of ORP2 participate in the oxysterol binding, 
mutations were introduced in several positions. Amino acid substitutions were 
designed based on the analysis of the structure of crystallized yeast ORP-homologue 
Osh4p (Im et al., 2005) and the three-dimensional model of ORP2 structure with 
bound 25OHC (II, fig. 2A). Mutations were generated by site-directed mutagenesis; 
the GST-tagged proteins were expressed in E. coli and purified. Their ability to bind 
40 nM 25OHC was tested using the charcoal-dextran sterol-binding assay.  
According to the model, nonpolar amino acid methionine 93 resides in the N-
terminal lid region of ORP2 close to the hydroxyl-group in the 25-carbon (II, fig. 
2B). Substitution of this residue with positively charged lysine was thus expected to 
modify the sterol binding. However, this mutation resulted in only a small reduction 
in the 25OHC binding. Hydrophobic phenylalanine 152 corresponds to hydrophobic 
leucine 111 of Osh4p, which is thought to stabilize the core fold of the protein. 
L111D mutation in Osh4p abrogated cholesterol binding and biological function of 
Osh4p. When F152 of ORP2 was mutated to negatively charged aspartic acid, the 
reduction in oxysterol binding of ORP2 was again not significant, suggesting that 
F152 is not essential for the oxysterol binding. Interestingly, the purified F152D 
ORP2-protein was partially fragmented in SDS-PAGE analysis, suggesting that this 
residue is important for the stability of ORP2 (II, fig. 2C). Phenylalanine 103 is 
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predicted to be located in the sterol-binding pocket near the B-ring of 25OHC, and 
introducing bulkier, nonpolar tryptophan to the place of phenylalanine was expected 
to hinder oxysterol binding to the pocket. However, the oxysterol binding of F103W 
mutant was only slightly inhibited.  
The ORP2 mutants most defective in oxysterol binding were K150A and I249W (II, 
fig. 2D). According to the ORP2 model, lysine 150 is located near the 25-carbon of 
the sterol. In the alignment of Osh4p and ORP2 it corresponds to K109 in Osh4p, 
which is located near the entrance of the binding pocket and suggested to participate 
in the membrane binding mediated by phosphate groups of PIP. Substitution of 
lysine by the smaller, nonpolar alanine in ORP2 was expected to create more space 
and thus affect oxysterol binding specificity. Indeed, 25OHC binding of this mutant 
was only 70% of the wild-type ORP2 binding, suggesting that K150A mutation 
affects the local shape of the binding pocket so that oxysterol cannot fit there. 
Another possibility is that as a positive amino acid K150 forms electrostatic 
interactions with negative residues of the protein, which could be important for its 
proper fold. Mutation of lysine to neutral amino acid alanine may compromise these 
interactions.     
Hydrophobic isoleucine 249 is located close to the C and D rings of the sterol. As a 
bulkier amino acid, tryptophan in the place of isoleucine was hypothesized to 
interfere with the sterol binding. I249W turned out to be the mutation that most 
efficiently blocks the oxysterol binding. It was also tested for 22(R)OHC binding, 
which was reduced 75% compared with the wild-type ORP2 (III, fig. 1A). I249 is 
not conserved from Osh4p to ORP2 and the mutation was designed based only on 
the molecular model of ORP2. This finding confirms that the three-dimensional 
model of ORP2 is at least in part valid. Together these results also confirmed the 
existence of a sterol-binding pocket in ORP2 and offered a new mutant as a valuable 
tool to study the effect of ORP2 oxysterol binding on cellular lipid metabolism. 
5.1.3 ORP2 binds cholesterol (III)  
Cholesterol binding of ORP2 would offer an explanation to the finding that ORP2 
overexpression affects the intracellular cholesterol metabolism (Laitinen et al., 
2002). Abnormally high amounts of cytosolic protein even with low affinity towards 
cholesterol could transport cholesterol from the ER to the plasma membrane and 
thus enhance cholesterol efflux. In addition, other ORPs such as OSBP (Wang, P.Y. 
et al., 2005), ORP4 (Wyles et al., 2007) and Osh4p (Im et al., 2005) were previously 
shown to bind cholesterol.  OSBP and ORP9 were even demonstrated to transfer 
cholesterol between vesicles (Ngo and Ridgway, 2009) 
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In live cells overexpressed ORP2 was not able to bind [3H]photocholesterol (results 
not shown). However, cholesterol binding of ORP2 was still examined in vitro. 
Since cholesterol is far less water-soluble than oxysterols, it cannot be used in the 
charcoal-dextran sterol-binding assay. Therefore we designed an assay, in which 
[3H]cholesterol is solubilized with methyl-β-cyclodextrin, a cyclic oligosaccharide 
molecule that in an aqueous environment form a cylindrical shape, which is able to 
bind a cholesterol molecule inside the cavity, thus making it water-soluble. 
[3H]cholesterol-cyclodextrin complexes are then incubated with GST-tagged fusion 
proteins bound to glutathione sepharose beads and the radioactivity associated with 
the beads is measured. GST was used as a negative control and GST-tagged START 
(steroidogenic acute regulatory protein related lipid transfer) domain of MLN64 
(Metastatic lymph node 64) as a positive one. 
In the assay, GST-ORP bound cholesterol approximately twice as much as the 
negative control GST (III, fig. 1B). Cholesterol binding was still modest compared 
with that of MLN64 START. When the assay was done in the presence of 40-fold 
molar excess of unlabeled 22(R)OHC, cholesterol was no longer bound to GST-
ORP2. These results indicate that ORP2 is capable of binding cholesterol in the 
same binding pocket as oxysterols. This is different to OSBP, in which the bound 
cholesterol could not be replaced by 25OHC (Wang, P.Y. et al., 2005) suggesting 
two binding sites for sterols.  
Together with the fact that ORP2 is a soluble, cytosolic protein, the ability to bind 
cholesterol makes ORP2 a potential cholesterol transport protein. Although the 
transport activity might not be relevant in vivo, it could be detected in cells 
overexpressing ORP2 as changes in cholesterol metabolism.      
5.2 Intracellular targeting of ORP2 (III) 
5.2.1 ORP2 associates with lipid droplets  
In previous studies ORP2 has been shown to localize to the Golgi apparatus 
(Laitinen et al., 2002; Xu et al., 2001). However, in most cell lines ORP2 has been 
observed to be soluble throughout the cytoplasm, although it has also been detected 
in cell membrane fractions. Since ORP2 was found to be a lipid-binding protein and 
therefore potentially regulated by cellular lipid status, its localization was studied in 
conditions with different amounts of lipids using the epidermal carcinoma cell line 
A431. In these cells, under normal culture conditions with 10% FBS (Fetal bovine 
serum), ORP2 staining was cytosolic, but also punctate structures and small spheres 
could be detected (III, fig. 2A). Strikingly, when A431 cells were treated with oleic 
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acid-BSA (bovine serum albumin) to induce the formation of intracellular lipid 
droplets, the localization of overexpressed ORP2 was changed. ORP2 antibody 
staining was no longer cytosolic, but formed small circles (III, fig. 2D-F). 
Interestingly, the interior of these circles was stained with a neutral lipid stain 
BODIPY 493/503 confirming that these structures were lipid droplets. BODIPY 
493/503 staining of cells cultured under normal growth conditions showed that 
ORP2 localization to lipid droplets was not induced by oleic acid-BSA-loading, 
since it could be detected also in normal conditions, in which small lipid droplets 
can be observed.  
Lipid droplet localization was proven to be specific by many control experiments. 
First of all, overexpressed, Xpress-tagged ORP2 was detected in lipid droplets with 
both anti-Xpress antibody and polyclonal ORP2 antibody (described by Laitinen et 
al., 2002). Secondly, HcRed-tagged ORP2 localized to lipid droplets also in non-
permeabilized cells, showing that the targeting is not an artefact resulting from the 
treatment of the cells for immunofluorescence microscopy (III, fig. 3D-F). Thirdly, 
the localization was not cell type specific, because overexpressed ORP2 was 
detected in lipid droplets also in HeLa, HepG2, Cos7, HuH7 and Hek293 cells (data 
not published). Finally, also untagged ORP2 targeted to lipid droplets in TREx HeLa 
cells induced to express ORP2 proving that the tag is not affecting the targeting (III, 
fig. 3A-C). 
ORP2 is endogenously expressed in A431. To determine if also the endogenous 
ORP2 localizes to lipid droplets, A431 cells were treated overnight with oleic acid-
BSA and the cells were stained with ORP2 antibody and BODIPY 493/503. In these 
conditions, ORP2 staining was concentrated in the area where lipid droplets resided 
(III, fig. 3G-I). Clear ring-like staining was not observed, as in ORP2 overexpressing 
cells, which could result from low level of endogenous ORP2 in these cells. The 
specificity of the ORP2 antibody in this experiment was confirmed by pre-
incubating the antibody with purified GST-ORP2 before adding to the cells. The 
pre-incubation inhibited the ORP2 staining in the area of lipid droplets (III, fig. 3G-
I). 
5.2.2 22(R)hydroxycholesterol inhibits lipid droplet targeting of ORP2 
Because ORP2 targeted to lipid droplets in the standard growth conditions, it was 
expected that some other growth condition could inhibit the targeting. The Golgi 
translocation of OSBP is induced by cholesterol depletion or 25OHC treatment. We 
therefore studied if the addition of oxysterols would inhibit the lipid droplet 
localization of ORP2. A431 cells transfected with ORP2-expression plasmid were 
treated overnight with oleic acid-BSA and different oxysterols. The addition of 5 
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M 7KC, 24(S)OHC, 25OHC and 27OHC did not significantly affect the targeting. 
However, when the cells were treated with 5 M 22(R)OHC, which is the highest 
affinity ligand of ORP2 so far, the lipid droplet targeting was clearly inhibited (III, 
fig. 6A-C). In these cells ORP2 staining was dispersed across the cytoplasm, not 
evenly, but showing a dotty-like appearance.  
The effect of 22(R)OHC was also studied in oleic acid-BSA loaded TREx HeLa 
cells induced to express ORP2. In these cells ORP2 targeting to lipid droplets is 
somewhat different than in A431 cells. Whereas in A431 cells ORP2 staining 
surrounds almost every lipid droplet inside one cell, in TREx HeLa cells ORP2 
staining is detected only in part of the lipid droplets (III, fig. 3A-C). When 
22(R)OHC is added to TREx HeLa cells, the lipid droplet staining of ORP2 vanishes 
more dramatically and the cytoplasmic staining of ORP2 is more even than in A431 
cells (III, fig. 6D-F). In addition, some plasma membrane staining can be seen. It is 
thus possible that in some cell types 22(R)OHC induces the translocation of ORP2 
to other membranes such as the plasma membrane. In hepatic HuH7 cells the plasma 
membrane staining of overexpressed ORP2 is often detected, also without the 
addition of 22(R)OHC  (data not shown). The possible targeting to plasma 
membrane requires further investigation since it might offer more evidence for the 
hypothesis that overexpressed ORP2 can transport cholesterol to the plasma 
membrane.   
The concentration of 5 M is physiologically high for oxysterols (van Reyk et al., 
2006). Therefore we studied the effect of 0.5 M and 0.05 M 22(R)OHC on ORP2 
lipid droplet targeting in ORP2 transfected A431 cells. The concentration of 0.05 
M was not able to remove ORP2 from the lipid droplets, but 0.5 M showed a 
small effect, although the effect was more subtle than with 5 M 22(R)OHC (III, fig. 
6N-O). The fact that the oxysterol effect on ORP2 targeting is dependent on the 
concentration supports the view that ORP2 localization and thereby also its function 
is directly regulated by oxysterols. 
We then wanted to ensure that the effect of 22(R)OHC was due to its binding to 
ORP2 and not by a secondary effect. The ORP2 mutant I249W, which is defective 
in oxysterol binding, was expressed in oleic acid-BSA loaded A431 cells in the 
presence or absence of 5 μM 22(R)OHC. In the absence of oxysterol ORP2 I249W 
was targeted to the lipid droplets like the wild-type protein (III, fig. 6G-I). However, 
also in the presence of 22(R)OHC ORP2 I249W remained associated with lipid 
droplets (III, fig. 6J-L) unlike the wild-type protein, which lost its lipid droplet 
association. These results clearly indicate that the ligand binding induces the 
translocation of ORP2 from the lipid droplet surface to a cytoplasmic location.     
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5.2.3 The role of FFAT-motif in the lipid droplet targeting of ORP2 
Membranes of ER have been regarded as a source of the monolayer surrounding 
lipid droplets and thus ER can often be detected in the close proximity of lipid 
droplets (Walther and Farese, 2008). ORP2 has an FFAT-motif, which is found in 
many lipid binding proteins and mediates their interaction with an ER membrane 
protein VAP-A (Loewen et al., 2003). Therefore it was possible that ORP2 localizes 
to the ER membranes surrounding the lipid droplets. To investigate this possibility, 
we examined the role of the FFAT-motif in the localization of ORP2 and carried out 
immunoelectron microscopy to visualize the ORP2 localization at the ultrastructural 
level.    
Interaction of ORP2 with VAP-A was previously suggested by Wyles and Ridgway 
(2004) and we wanted to confirm the result, because the binding seemed rather 
weak. ORP2 was translated in vitro, labeled with [35S]methionine, and subjected to 
pull-down with GST-tagged VAP-A bound to glutathione sepharose beads. 
Complexes associated with the beads were separated in SDS-PAGE and the 
radioactive, bound protein was detected by autoradiography. In vitro translated 
ORP2 was clearly bound to GST-VAP-A as compared with GST alone (Figure 5). 
Next we designed an ORP2 mutant, in which the FFAT-motif was disrupted. Amino 
acids 6EFFDA10 that constitute the FFAT-motif of ORP2 were mutated to 
6EVVVA10 using site-directed mutagenesis. VAP-A binding of the mutant (ORP2 
mFFAT) was determined as previously. ORP2 mFFAT showed no binding to GST-
VAP-A (Figure 5) confirming that FFAT-motif of ORP2 was responsible for the 
VAP-A interaction. 
The effect of mFFAT mutation on ORP2 localization was then studied. ORP2 
mFFAT was expressed in A431 cells treated with oleic acid-BSA and ORP2 was 
detected with rabbit ORP2 antibody. In cells expressing ORP2 mFFAT the lipid 
droplet targeting was inhibited and ORP2 showed a cytosolic localization 
comparable to that of wild-type ORP2 in 22(R)OHC treated cells (Figure 5). This 
suggests that the disturbance of VAP-A interaction results in ORP2 targeting to the 
cytoplasm. The result can also imply that the wild-type ORP2 is not in the surface 
on the lipid droplets but in the ER membranes surrounding lipid droplets, where 
VAP-A resides. However, immunoelectron microscopy studies on the localization of 
ORP2 confirmed that overexpressed ORP2 is on the lipid droplets, and no staining 
of ORP2 was detected in the ER (III, fig. 4). On the other hand, VAP-A was not 
detected on the surface of lipid droplets or in the ER membranes surrounding lipid 
droplets, as judged by immunofluorescence microscopy. These results indicate that 
either the FFAT-motif mediates an interaction of ORP2 with a still unknown lipid 
droplet protein, or that the mutation in the FFAT-motif disturbs the fold of ORP2, 
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which results in a fold reminiscent of the ligand-bound form of ORP2. The FFAT-
motif of ORP2 resides near the lid-region of ORP2, which supports the latter 
explanation.  
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Figure 6. Mutation in the FFAT-motif of ORP2 inhibits the lipid droplet association. A. 
VAP-A binding of ORP2 was determined by translating ORP2 wild-type or 
FFAT-mutant (ORP2mFFAT) in vitro and pulling down the translated 
proteins with GST or GST-VAP-A. T = in vitro translation reaction mixture, 
10% of the total amount loaded. B-D. The A431 cells were transfected with 
ORP2mFFAT and treated with 350 μM oleic acid-BSA. ORP2mFFAT was 
stained with ORP2 antibody (B) and lipid droplets with BODIPY 493/503 (C). 
A merge is shown in (D). Bar, 10 μm. The effect was quantified (E) by 
determining the proportion of cells displaying clear LD association of ORP2 
wild-type (wt) or FFAT-mutant (mFFAT). The data represents mean ± S.E.M 
from three coverslips, 100 transfected cells counted from each. 
There are many possible ways by which ORP2 can attach to the surface monolayer 
of lipid droplets. ORP2 binds phosphoinositides, which can mediate the binding. 
PIP-binding of ORP2 was not very specific for any particular PIP, suggesting that 
ORP2 has a positively charged region that may form electrostatic interactions with 
negatively charged phospholipids. This is supported by the PIP-binding result, in 
which ORP2 binding seems to be proportional to the amount of phosphate groups in 
PIP (I, fig. 9).  
There is no common amino acid sequence motif in lipid droplet proteins, but the 
targeting rather seems to depend on larger three-dimensional structures. One way of 
binding to lipid droplet monolayer is an amphipatic α-helix that forms hydrophobic 
interactions with membrane lipids. For example, a member of the perilipin protein 
family TIP47 is suggested to use a bundle of four amphipatic helices as a part of a 
hydrophobic cleft to associate with the monolayer of lipid droplets (Hickenbottom et 
al., 2004). However, the interaction of ORP2 with lipid droplets seems rather weak 
arguing against strong hydrophobic interactions. First, ORP2 has not been found in 
any of the studies investigating the proteome of the lipid droplets from mammalian 
cells (Brasaemle et al., 2004; Fujimoto et al., 2004; Liu et al., 2004; Umlauf et al., 
2004). Second, we were not able to detect endogenous ORP2 in lipid droplet 
fractions isolated from A431 cells (unpublished findings). These findings suggest 
that the lipid droplet targeting of ORP2 would more likely be mediated by an 
interacting protein. The interaction of ORP2 with TIP47 and triglyceride lipases 
ATGL and HSL were studied by co-immunoprecipitation, but no interaction was 
detected (data not published).  
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5.3 ORP2 regulates cellular cholesterol metabolism 
5.3.1 ORP2 inducible TREx HeLa cell lines (I) 
The previous studies examining the role of ORP2 in cellular lipid metabolism were 
done with Chinese hamster ovary-K1 (CHO-K1) cell lines that constitutively 
expressed ORP2 at relatively high levels (Käkelä et al., 2005; Laitinen et al., 2002). 
Constitutive expression of a protein can lead to effects that are due to the adaptation 
of the cells to the primary effect of the protein. Mutations may form in rapidly 
dividing transformed cell lines and only those cells that can handle the 
overexpression and its effects survive, and thus they may represent a skewed model. 
This disadvantage can be partially overcome by using multiple clones of 
overexpressing cells. Another way is to use stable cell lines that can be induced to 
overexpress a protein, which makes it possible to observe the acute effects of the 
overexpression. There are also advantages in using only one cell line, from which 
both overexpressing and non-expressing control cells can easily be obtained. We 
created ORP2 HeLa cell lines, in which the expression of ORP2 is under the control 
of a tetracycline-regulated repressor and can therefore be induced with doxycycline. 
In the following studies we used three independent cell lines 21f3, 38b10 and 40d5, 
which were obtained by single cell cloning of transfected cells. In these cell lines 
ORP2 expression was high already after 20 h induction with doxycyclin, but 42 h 
was used to detect the changes that ORP2 expression causes. The frequency of 
ORP2 overexpressing cells was high, over 90%. Uninduced cells of cell lines 21f3 
and 38b10 had some leakage of ORP2 expression but were still markedly induced 
by doxycycline, while the third cell line 40d5 displayed tight regulation (I, fig. 1). 
Endogenous ORP2 could not be detected by Western blotting in HeLa cells. 
5.3.2 Inducible ORP2 expression enhances cholesterol efflux (I) 
CHO-cells overexpressing ORP2 previously showed a higher rate of cholesterol 
efflux to many extracellular acceptors. Using ORP2 inducible HeLa cells we 
examined if this result can be reproduced in the human cell line. Cells from three 
independent lines were concomitantly labeled with [14C]cholesterol and treated with 
doxycycline to induce ORP2 overexpression. After 40 hours of labeling and 
induction, cholesterol efflux to several acceptors was determined. When using 20% 
human serum as an extracellular cholesterol acceptor in the medium, 
[14C]cholesterol efflux was approximately 15% higher in ORP2 induced cells from 
all three cell lines than in uninduced control cells (I, fig.2). To specifically measure 
cholesterol efflux employing different mechanisms, apoA-I and HDL2 were used as 
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acceptors. Again, ORP2 induced cells effluxed cholesterol more efficiently to both 
acceptors than the untreated cells, when the efflux time was 4 hours (I, fig.2). Even 
when only BSA was added to the efflux medium, cholesterol efflux was enhanced in 
ORP2 induced cells. We then wanted to exclude the possibility that ORP2 
expression induces the shedding of plasma membrane or exocytosis of small 
vesicles containing cholesterol. We measured the efflux to medium with no 
cholesterol acceptors and again detected slightly more cholesterol in the medium of 
ORP2 induced cells than in non-induced cells. However, the rate of membrane 
shedding was so low that it cannot explain the changes in cholesterol efflux to the 
different acceptors. These results propose that ORP2 does not affect any specific 
cholesterol efflux mechanism such as those mediated by ABCA1 or ABCG1, but 
rather influences the distribution or transport of intracellular cholesterol. In addition, 
these results confirm those obtained with ORP2 overexperssing CHO cells. 
The next question to be addressed was if cholesterol in ORP2 overexpressing cells is 
transported faster from the intracellular pool to the plasma membrane or if it is just 
more readily diffused from the plasma membrane. This was studied by exposing 
cells to cyclodextrin, which rapidly extracts cholesterol from the plasma membrane. 
If the treatment is really short, the intracellular cholesterol trafficking machinery 
does not have time to replace the cholesterol. TREx HeLa cells were labeled with 
[14C]cholesterol and simultaneously induced with doxycycline for 42h. Cells were 
incubated for 5 minutes with 5 mM methyl-β-cyclodextrin, after which the 
proportion of cholesterol in the medium was determined. Significantly more 
[14C]cholesterol was extracted by cyclodextrin from ORP2 expressing cells than 
from uninduced cells (I, fig. 3A). The result implies that there is more cholesterol in 
the plasma membrane or the specific lipid environment in the plasma membrane 
facilitates the cholesterol efflux from ORP2 expressing cells. 
Cholesterol in the plasma membranes facilitates the formation of special membrane 
microdomains, lipid rafts, in which cholesterol and sphingolipids are preferentially 
clustered (Simons and Ikonen, 1997). Some membrane lipids can be isolated based 
on their resistance to detergents at low temperatures unlike the rest of the membrane. 
These lipid fractions with a high melting point are called detergent resistant 
membrane domains, DRMs. In model systems cholesterol is shown to be released 
more slowly from sphingomyelin-rich membranes (Lund-Katz et al., 1988) 
indicating that in ORP2 expressing cells more cholesterol is associated with non-raft 
membranes than in control cells. Therefore we examined the cholesterol distribution 
between raft and non-raft membranes in ORP2 expressing cells. TREx HeLa cells 
were labeled with [14C]cholesterol and induced with doxycycline as before. Cells 
were lysed in ice-cold 1% Triton X-100 to solubilize all but DRMs representing the 
rafts. DRMs were then isolated by Optiprep-gradient ultracentrifugation, in which 
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DRMs float in the top two fractions. The distribution of [14C]cholesterol between 
DRM fractions and the other fractions was similar in ORP2 induced and uninduced 
cells of all three cell lines thus providing no explanation for the enhanced 
cholesterol efflux (I, fig. 3C).     
Next we compared the lipid composition of the plasma membrane of ORP2 induced 
and uninduced cells. Plasma membranes of the cells were isolated using colloidal 
silica method and their lipids were extracted. Cholesterol amount was determined by 
enzymatic methods and was similar in ORP2 expressing and uninduced cells thus 
providing no explanation for the efflux difference (I, fig. 3B). The amount of 
different phospholipids and their fatty acid compositions was determined by liquid 
chromatography-electrospray ionization mass spectrometry. Again, no difference 
was observed between ORP2 expressing and uninduced cells. 
Recent findings suggest that sterols are located in the cytoplasmic leaflet of plasma 
membrane bilayer (Mondal et al., 2009). Based on their studies on red cells, Steck et 
al. (2002) have estimated that the half-time for cholesterol flip-flop movement is 
relatively rapid, only one second. Although many aspects of plasma membrane lipid 
content and organization were studied, it is still possible that ORP2 overexpression 
alters the rate of flip-flop movement of cholesterol from the inner leaflet of the 
bilayer to the other one. Since ORP2 is occasionally detected in the plasma 
membrane, ORP2 overexpression could be imagined to increase the proportion of 
cholesterol in the outer leaflet which could further increase the rate of cholesterol 
efflux. This could also at least in part explain the result of increased extractability of 
cholesterol by cyclodextrin from ORP2 overxepressing cells. 
Another possible explanation for the enhanced cholesterol efflux could be stimulated 
cholesterol transport from intracellular membranes to the plasma membrane. 
Because it is now known that ORP2 is capable of binding cholesterol, it is possible 
that a high expression level of ORP2 enhances the transport of cholesterol to the 
plasma membrane. The transport of newly synthesised cholesterol from the ER to 
the plasma membrane was studied in ORP2 overexpressing CHO-cells, which 
display more pronounced increment in cholesterol efflux than the ORP2 expressing 
HeLa cells. When the total cell cholesterol was labeled with [14C]cholesterol and the 
newly synthesised cholesterol with tritium, the amount of newly synthesised 
cholesterol in the plasma membrane was higher in ORP2 overexpressing cells than 
in control cells, also when compared with [14C]cholesterol (I, fig. 4). This suggests 
that ORP2 enhances specifically the transport of cholesterol from the ER to the 
plasma membrane. 
Of the other ORPs, OSBP, ORP9 and Osh4p have been shown to be able to transfer 
cholesterol between vesicles (Ngo and Ridgway, 2009; Raychaudhuri et al., 2006). 
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Taken into account the suggested similarity of the sterol-binding pocket of different 
ORPs, it seems possible that also ORP2 is able to transfer cholesterol.  
5.3.3 The effect of ORP2 on cholesterol esterification 
The next question to be addressed was that if cholesterol is cleared more rapidly 
from the ORP2 expressing cells, where does it originate from? Obvious organelles 
were lipid droplets, from which cholesterol could be released. Indeed, cholesterol 
esterification was inhibited in CHO cells overexpressing ORP2 (Laitinen et al., 
2002), suggesting that the cells respond to the loss of cholesterol by inhibiting its 
storage. In addition, even under conditions in which cholesterol esterification was 
blocked with an ACAT inhibitor, ORP2 expressing CHO cells still showed 
enhanced cholesterol efflux compared to control cells. This support the fact that 
enhanced cholesterol efflux leads to reduced esterification and not the other way 
around (I, fig. 5B). 
T h e  e f f e c t  o f  i n d u c i b l e  O R P 2  o v e r e x p r e s s i o n  ( I )  
What then happens in ORP2 induced HeLa cells? Do they also inhibit cholesterol 
esterification in response to enhanced efflux? TREx HeLa cells were labeled with 
[14C]cholesterol for 42 h in the presence or absence of doxycycline and the amount 
of [14C]cholesterol incorporated to cholesteryl esters was determined. Interestingly, 
in ORP2 induced cells from two cell lines (21f3, 40d5) the amount of 
[14C]cholesterol esters was significantly higher than in uninduced cells, while in the 
third cell line no change was observed (I, fig. 5A). The discrepancy between ORP2 
overexpressing CHO cells and TREx HeLa cells could be explained by the 
assumption that the CHO cells have adapted to the high rate of cholesterol efflux by 
inhibiting cholesterol esterification. Maybe only the ORP2 expressing CHO cells 
that have developed a mutation that leads to inhibited cholesterol esterification have 
survived the selection of the ORP2 cell lines. In contrast, TREx HeLa cells that have 
expressed ORP2 only for 42 h have not had time to adapt to the high rate of 
cholesterol efflux. Therefore the increment in esterification could represent a more 
direct effect of ORP2 overexpression. How is the increased cholesterol esterification 
accomplished then? ACAT resides in the ER membranes and is mostly regulated by 
availability of its substrates, cholesterol and fatty acids (Seo et al., 2001; Zhang et 
al., 2003). Also oxysterols activate ACAT (Zhang et al., 2003). If ORP2 enhanced 
the transport of cholesterol from the ER to the plasma membrane, the ER pool 
would be diminished leading to decreased rate of cholesterol esterification, which is 
in contrast to our findings. On the other hand, the decreased ER pool of cholesterol 
can be replenished by newly-synthesized cholesterol or cholesterol from 
lipoproteins. Indeed, we found later that the amount of unlabeled cholesteryl esters 
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was not increased in ORP2 overexpressing HeLa cells, when the cells were cultured 
with lipoprotein deprived serum (see 5.3.4).  
T h e  e f f e c t  o f  O R P 2  s i l e n c i n g  ( I I I )  
After studying the effects of overexpressed ORP2, we wanted to clarify the role of 
endogenous ORP2 in cholesterol metabolism, which is possible by using gene 
silencing with small interfering RNAs (siRNA). However, we had to change the cell 
line, since the endogenous expression of ORP2 in HeLa cells is below the detection 
level of Western blotting. The human A431 cell line was chosen, because it has a 
high endogenous expression level of ORP2 and it was already used in the ORP2 
localization studies. Endogenous ORP2 expression was silenced with three siRNAs, 
which all resulted in at least 80% decrease in the ORP2 protein level (III, fig. 7A). 
A431 cells were treated with ORP2 and control siRNAs for 48 h and cholesterol 
esterification was determined as incorporation of [14C]cholesterol to cholesteryl 
esters. Cholesterol esterification in cells treated with control and ORP2 siRNAs was 
similar. However, when the cells were treated with oleic acid-BSA to induce the 
formation of lipid droplets, a significant difference was observed. Cells treated with 
control siRNA had somewhat increased incorporation of [14C]cholesterol to 
cholesteryl esters in the presence of oleic acid-BSA, obviously due to a higher 
amount of ACAT fatty acyl substrate, but the increase in the amount of 
[14C]cholesterol incorporated was much higher in ORP2 silenced cells. This 
indicates that endogenous ORP2 functions to decrease the amount of cholesteryl 
esters, but only in conditions that stimulate the formation of triglycerides and 
cholesteryl esters. Whether the increased amount of cholesteryl esters in ORP2 
silenced cells results from enhanced ACAT activity or inhibited breakdown of 
cholesteryl esters is not clear. We made efforts to clarify, which alternative could 
explain the increased amount of cholesteryl esters, but with no success (data not 
published). 
When considering the suggestion that ORP2 stimulates cholesterol hydrolysis on the 
surface of lipid droplets and the finding that its lipid droplet localization is inhibited 
by 22(R)OHC, a following scheme can be suggested. Since 22(R)OHC is an 
intermediate in the synthesis of steroid hormones, it can be hypothesized to 
accumulate in steroidogenic cells, when the steroid hormone synthesis is active. 
22(R)OHC could bind to ORP2 and remove it from the lipid droplets to inhibit the 
hydrolysis of cholesteryl esters, which is needed to deliberate free cholesterol for the 
steroid hormone synthesis. By this very hypothetical mechanism ORP2 could 
mediate the possible negative feed-back effect of 22(R)OHC on steroid hormone 
synthesis. Supporting the hypothesis, Laitinen et al. showed (2002) that ORP2 
protein is well detected in steroidogenic mouse tissues, such as ovary, testis and 
adrenals. 
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Taken together, ORP2 overexpression results in increased esterification in HeLa 
cells and reduced esterification in CHO cells (Laitinen et al., 2002). On the other 
hand, ORP2 silencing results in increased amount of cholesteryl esters, but only in 
lipogenic conditions. To compare these results same cell lines and culture conditions 
should be used. It is possible that the ORP2 effects on cholesterol esterification are 
dependent on another protein, which is expressed or active only in some cell types 
or in some culture conditions. ORP2 localization is also slightly different in different 
cell types, which may partially explain the differences in the results. 
5.3.4 Effect of ORP2 overexpression on cellular cholesterol levels (I) 
The increased rate of cholesterol efflux and esterification in TREx HeLa cells 
induced to overexpress ORP2 would most probably lead to a decreased amount of 
cellular free cholesterol. The amount of unlabeled cholesterol was measured from 
ORP2 induced and uninduced cells cultured either in normal 10% FBS containing 
medium or in medium with 5% lipoprotein deficient serum. Total cholesterol and 
free cholesterol were quantified from cell lysates using two separate enzymatic 
assays and the amount of cholesteryl esters was calculated by subtracting free 
cholesterol from the value of total cholesterol. The results supported the findings 
obtained by radioactive labeling experiments. In the presence of FBS the ORP2 
induced cells from cell lines 21f3 and 40d5 had more cholesteryl esters than 
uninduced cells, and the amount of free cholesterol was decreased so that there was 
no change in the amount of total cholesterol (I, fig. 6). In cells grown without 
lipoproteins the amount of cholesteryl esters was not altered in ORP2 expressing 
cells probably due to lack of cholesterol from the medium and subsequently 
inhibited cholesterol esterification. The amounts of total and free cholesterol were 
both slightly decreased in ORP2 induced cells. These results suggest that enhanced 
cholesterol efflux and esterification leads to a decreased amount of free cholesterol 
in ORP2 overexpressing cells. 
Endoplasmic reticulum is an important organelle for the regulation of cellular 
cholesterol metabolism. The cholesterol level in the ER determines the activity of 
SREBP transcription factors, ACAT, and HMG-CoA reductase (Chang et al., 1997; 
Espenshade and Hughes, 2007; Goldstein et al., 2006). The increased amount of 
cholesteryl esters in ORP2 induced HeLa cells implies that the amount of cholesterol 
in an ER pool accessible to ACAT is higher than in uninduced cells.   
The activity of HMG-CoA reductase can also be regarded as an indicator of ER 
cholesterol levels. Therefore the HMG-CoA reductase activity was measured from 
ORP2 induced and uninduced TREx HeLa cells. In addition, it was important to see, 
whether the ORP2 expressing cells respond to lower levels of free cholesterol by 
 65 
upregulating cholesterol biosynthesis. Indeed, ORP2 expression led to higher 
activity of HMG-CoA reductase in all three cell lines, when it was measured from 
semipurified membranes (I, fig. 6A), indicating that the ER cholesterol pool 
accessible to HMG-CoA reductase is diminished. 
There seemed to be an apparent discrepancy between the results of cholesterol 
esterification and HMG-CoA reductase activity. Is it possible that both cholesterol 
synthesis and esterification are simultaneously stimulated? A recent study suggested 
that there are at least two distinct cholesterol pools in ER that regulate the SREBP 
activity and ACAT (Kristiana et al., 2008). These pools respond to increased 
cholesterol uptake with different kinetics. If also the cholesterol pool regulating the 
activity of HMG-CoA reductase is distinct from the ACAT substrate pool, the 
results of ORP2 overexpression can be explained by different effects of ORP2 on 
different pools. Upregulated cholesterol biosynthesis can also be thought to 
replenish the ER cholesterol pool to be used as ACAT substrate.  
5.3.5 Effect of ORP2 overexpression on LDL internalization (I) 
Cholesterol uptake is known to be mainly regulated in the level of LDL receptor 
expression. The LDL receptor gene has a binding site (SRE) for SREBP, which is 
upregulated, when the cholesterol level in the ER is low. Therefore it was probable 
that if the cholesterol pool in the ER regulating the Scap-SREBP transport was 
diminished in ORP2 expressing cells, LDL receptor expression would be 
upregulated. We examined the LDL receptor expression level from ORP2 induced 
and uninduced HeLa cells by Western blot. When the cells were cultured in the 
standard serum containing medium, LDL receptor expression was clearly 
upregulated in ORP2 induced cells compared to the control cells (I, fig. 7A). When 
the cells were cultured in medium containing lipoprotein deficient serum, LDL 
receptor expression level was similarly increased in both ORP2 induced and 
uninduced cells. This suggests that the upregulation of LDL receptor by the loss of 
cholesterol due to blocked availability of cholesterol from the medium is much 
higher than the upregulation caused by ORP2 overexpression. 
We next investigated if the enhanced expression of LDL receptor results in 
stimulated uptake of LDL particles by endocytosis in ORP2 induced HeLa cells. 
ORP2 induced and uninduced HeLa cells were incubated with fluorescent DiI-LDL 
(1,1´-dioctadecyl-3,3,3´,3´-tetramethyl-indocarbocyanineperchlorate-labeled LDL) -
particles for 15 minutes, after which the intracellular fluorescence was quantified. 
The ORP2 induced cells internalized significantly more DiI-LDL than uninduced 
cells concordantly with the result of upregulated LDL receptor expression (I, fig. 
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7B-D). In this way ORP2 induced cells can apparently replace the cholesterol that is 
lost due to enhanced cholesterol efflux. 
5.4 Effect of ORP2 overexpression on endocytosis (I)    
Yeast Osh-proteins have been suggested to play important roles in endocytosis (Beh 
and Rine, 2004). Because OPR2 expressing HeLa cells had enhanced rate of LDL 
uptake, we wanted to investigate if it results, in addition to increased LDL receptor 
expression, from stimulated endocytosis. LDL in complex with LDL receptor is 
endocytosed via the clathrin-dependent pathway, which is also used by other 
complexes such as transferrin-transferrin receptor (Conner and Schmid, 2003). We 
measured the rate of clathrin-mediated endocytosis from ORP2 induced and 
uninduced HeLa cells using FITC-conjugated transferrin as a marker. The cells were 
treated for five minutes with FITC-transferrin, after which the intracellular 
fluorescence was quantified. ORP2 overexpression led to mild, not significant 
increase in transferrin internalization (I, fig. 8D-F) supporting the hypothesis that the 
stimulated uptake of LDL results mostly from upregulated LDL receptor expression. 
After internalization transferrin and transferrin receptor enter the endocytic route, 
where iron is released from transferrin, and recycle back to the plasma membrane 
(Maxfield and McGraw, 2004). If the recycling of transferrin to plasma membrane 
was faster in ORP2 cells, the possible effect of ORP2 in endocytosis would not be 
detected. Therefore we also examined the recycling of transferrin in ORP2 induced 
and uninduced cells. FITC-transferrin was first internalized for an hour at 16ºC and 
then chased for 5 to 15 minutes in the presence of excess unlabeled holo-transferrin 
to prevent the further internalization of FITC-transferrin. The intracellular 
fluorescence was quantified at two time points and expressed as percentage of the 
fluorescence before the chase (I, fig. 8G). The rate of transferrin recycling in ORP2-
induced cells was similar to uninduced cells supporting the result of ORP2 having 
only a mild effect on clathrin-dependent endocytosis.   
Different molecules and particles can be endocytosed by various mechanisms 
(Conner and Schmid, 2003). Macrophages can also take up LDL via LDL receptor-
independent way by fluid-phase endocytosis (Kruth et al., 2002). Fluorescently 
labeled dextran can be regarded as a marker for the fluid-phase endocytosis. We 
used rhodamine-dextran to measure the rate of fluid-phase endocytosis in ORP2-
induced and uninduced cells. After 15 minutes internalization intracellular 
fluorescence was quantified from the cells. Interestingly, ORP2 induced cells 
internalized significantly more rhodamine-dextran than uninduced cells (I, fig. 8A-
C).  
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Taken together, these results suggest that ORP2 overexpression stimulates fluid-
phase endocytosis, but clathrin-mediated endocytosis is mildly enhanced as well. By 
which mechanism is this achieved? Cholesterol amount on the plasma membrane 
has been shown to affect endocytosis (Pichler and Riezman, 2004). Also the effects 
of Osh deletions in yeast were suggested to result from disturbance of ergosterol 
levels. Although the amount and organization of plasma membrane lipids seemed to 
be similar in ORP2 induced and uninduced cells, the overall changes in cholesterol 
metabolism or a hypothetical change in the transbilayer distribution of cholesterol in 
ORP2 induced cells could have an influence on endocytosis. 
5.5 Effect of ORP2 on triglyceride metabolism (III) 
When examining the localization of ORP2 in A431 cells treated with oleic acid-
BSA, it could be observed that in ORP2 overexpressing cells lipid droplets were 
organized in a different way than in untransfected cells. In untransfected cells the 
lipid droplets were clustered together close to the nucleus, whereas in ORP2 
expressing cells the lipid droplets were dispersed throughout the cytoplasm and 
looked smaller (III, fig. 5). This implied that ORP2 could affect the metabolism of 
triglycerides. 
First we investigated if endogenous ORP2 has an effect on the synthesis of 
triglycerides. A431 cells were treated with control siRNA or ORP2 siRNA for 48 
hours, after which [3H]oleic acid-BSA was added to the cells. Cells were harvested 
at three time-points and the amount of radioactivity incorporated into triglycerides 
was determined. No difference was detected between ORP2 siRNA and control 
siRNA treated cells suggesting that ORP2 has no effect on triglyceride synthesis 
(data not published).  
Next we investigated the effect of ORP2 on triglyceride break-down. A431 cells 
were treated with siRNAs as previously and loaded overnight with oleic acid-BSA 
including [3H]oleic acid to stimulate the triglyceride formation and to radioactively 
label triglycerides. After the loading the cells were transferred to delipidated serum 
–containing medium to induce the hydrolysis of triglycerides. Cells were harvested 
at different time-points and the incorporation of [3H]oleic acid to triglycerides was 
measured. Already before the chase the amount of triglycerides was higher in ORP2 
siRNA treated cells than in control cells. When the value in zero time-point was set 
as 100%, it was evident that ORP2 silenced cells hydrolyzed triglycerides more 
slowly than the control cells (III, fig. 7). This suggests that endogenous ORP2 
stimulates the hydrolysis of triglycerides. The result is concordant with the previous 
finding showing that the amount of triglycerides is decreased in ORP2 
overexpressing CHO cells.  
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The result is also in accordance with the result of altered distribution of lipid 
droplets in ORP2 overexpressing A431 cells. During stimulated lipolysis in 3T3-L1 
adipocytes lipid droplets are fragmented into smaller ones (Marcinkiewicz et al., 
2006) probably to increase the lipid droplet surface area and binding region for 
lipases. It was recently shown that Arf1-COPI vesicle transport machinery is needed 
for the lipid droplet fragmentation and efficient lipolysis (Guo et al., 2008). In 
addition, many Rab-proteins, which control vesicular trafficking, are found in the 
surface of lipid droplets. OSBP has been shown to interact with ARF (Godi et al., 
2004) and other ORPs have been shown to bind different small GTPases as well 
(Johansson et al., 2005; Lehto et al., 2008). Therefore it is tempting to speculate that 
ORP2 could interact with ARF or other small GTPases, or regulate their activity, 
and that way affect the lipid droplet structure or mobilization.  
ORP2 could also participate directly in triglyceride hydrolysis. The best 
characterized mechanism of lipolysis is the classical pathway of catecholamine-
stimulated triglyceride hydrolysis in adipocytes (Watt and Steinberg, 2008). 
Adipocytes would thus be a good model to study ORP2 function further. One still 
poorly investigated area in cellular lipid metabolism is the coregulation of 
cholesterol and triglyceride metabolism. It could be speculated that ORP2 acts as a 
sterol sensor that regulates the release of fatty acids from triglycerides, as well as 
fatty acids and free cholesterol from cholesteryl esters according to the cellular 
sterol status. Cholesterol in membranes is preferably positioned next to lipids with 
saturated fatty acids (Simons and Vaz, 2004). Therefore, if the amount of cholesterol 
in cellular membranes is altered, also the fatty acid composition of membrane 
phospholipids has to change to preserve the composition and properties of the 
membranes. Triglycerides in lipid droplets act as a reservoir of fatty acids and ORP2 
could function there to control the release of fatty acid for the membrane 
regeneration. 
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6 SUMMARY AND CONCLUSIONS 
ORP2 is a member of OSBP-related protein family. ORPs have been implicated in 
various cellular functions such as the regulation of lipid metabolism, vesicle 
transport and cellular signaling. The studies on ORP2 have concentrated on cellular 
lipid metabolism. In previous studies the constitutive overexpression of ORP2 in 
CHO cells was shown to enhance cholesterol efflux, inhibit cholesterol esterification 
and decrease the amount of cellular triglycerides. 
In this study the role of ORP2 in lipid metabolism was investigated using two types 
of cell lines. Tetracycline-inducible stably transfected HeLa cell lines were 
employed to study the effects of acute ORP2 overexpression on cholesterol 
metabolism and endocytosis. A431 cells were employed to study the localization of 
ORP2 as well as the effect of ORP2 gene silencing on triglyceride and cholesteryl 
ester metabolism. Furthermore, we performed site-directed mutagenesis and sterol 
binding assays in vitro to study the ligand interactions of ORP2.   
In HeLa cells, inducible ORP2 overexpression led to enhanced cholesterol efflux to 
all the extracellular acceptors that were studied, suggesting that the effect was not 
specific to any particular efflux mechanism. The cholesterol amount and distribution 
in the plasma membrane were investigated to find the explanation for the enhanced 
cholesterol efflux. The only explanation that was not ruled out was the possibility 
that ORP2 could affect the distribution of cholesterol between the two leaflets of the 
plasma membrane bilayer. The other explanation for enhanced cholesterol efflux 
was suggested to be the stimulated cholesterol transport from intracellular 
membrane compartments to the plasma membrane. This was supported by the 
finding that ORP2 binds cholesterol and could thus induce changes in cholesterol 
trafficking when overexpressed.  
The enhancement of cholesterol efflux resulted in a decreased amount of free 
cholesterol in ORP2 induced HeLa cells. The cells were able to compensate for the 
loss of cholesterol by stimulating cholesterol biosynthesis and uptake. Upregulated 
LDL receptor expression was accompanied by stimulated uptake of LDL. In 
addition, fluid-phase endocytosis was stimulated in ORP2 induced HeLa cells 
indicating that excess ORP2 has a more general effect on endocytosis and not just on 
LDL receptor expression.  
Whereas cells usually respond to decreased amount of free cholesterol by inhibiting 
the storage of cholesterol as cholesteryl esters, ORP2 induced HeLa cells had more 
cholesteryl esters than the uninduced control cells. This result suggests that in HeLa 
cells the ER cholesterol pool that is used by the cholesterol esterifying enzyme 
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ACAT is affected differently from the pool that regulates the activity of SREBP-
transcription factors and HMG-CoA reductase. On the other hand, stimulated uptake 
and synthesis of cholesterol were able to provide enough cholesterol for cholesterol 
esterification. 
Cholesteryl esters are stored in cytoplasmic lipid droplets, where also ORP2 was 
found to localize. Ligand binding was shown to play a role in the lipid droplet 
targeting of ORP2. The ORP2 ligand with the highest affinity was found to be 
22(R)OHC, but the protein also binds other oxysterols and phosphoinositides. 
Treatment of cells with 22(R)OHC was demonstrated to inhibit the localization of 
ORP2 on the surface of the lipid droplets, suggesting that ORP2 localization and 
subsequently the function are regulated by the ligand binding. 
The function of endogenous ORP2 was investigated by silencing its expression in 
A431 cells. Silencing of ORP2 led to delayed hydrolysis of triglycerides, when the 
cells were shifted from lipogenic to lipolytic conditions. This suggests that ORP2 
stimulates the hydrolysis of triglycerides. When the formation of triglycerides was 
induced, ORP2 silencing also resulted in increased amount of cholesteryl esters, but 
this effect was not observed under normal cell culture conditions. This suggests that 
the amount of cellular triglycerides affects the activity of ORP2 in the regulation of 
cholesteryl ester metabolism. 
Taken these results together, we propose that ORP2 is a sterol-regulated protein 
localizing to the surface of lipid droplets, where it participates in the regulation of 
triglyceride and cholesteryl ester metabolism. Through cholesterol binding it can 
also have effects on cholesterol metabolism in other cellular locations. The possible 
cell type-specific functions of ORP2 and its role in metabolic disorders such as 
obesity or atherosclerosis remain to be clarified. 
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